## Contents

### Subject:  

<table>
<thead>
<tr>
<th>Abbreviations</th>
</tr>
</thead>
</table>

### 1. Introduction

| 1.1 Background | 1 |
| 1.2 Vision Statement of the National TB Control Programme | 1 |
| 1.3 Mission Statement of the National TB Control Programme | 2 |
| 1.4 Goal of Tuberculosis Control | 2 |
| 1.5 Objectives of the National Tuberculosis Control Programme | 2 |
| 1.6 Strategies for Control of Tuberculosis | 2 |
| 1.7 Activities of NTP | 3 |

### 2. General information about tuberculosis

| 2.1 Definition of Tuberculosis | 3 |
| 2.2 Difference between TB infection and TB disease | 3 |
| 2.2.1 TB infection | 3 |
| 2.2.2 TB disease | 4 |
| 2.3 Spread of tuberculosis | 4 |
| 2.4 Development of Tuberculosis | 4 |

### 3. Structure of the National TB Programme of Bangladesh | 5 |

### 4. Case finding and diagnosis

| 4.1 Signs and symptoms of TB | 6 |
| 4.2 Method of case findings | 6 |
| 4.3 organization of case findings | 6 |
| 4.3.1 By medical staff | 6 |
| 4.3.2 By non-medical persons | 7 |
| 4.4 Diagnosis | 7 |
| 4.4.1 Tools for diagnosis of TB | 7 |
| 4.4.2 Examination of sputum specimens | 8 |
| 4.5 Case definition | 9 |
| 4.5.1 Anatomical site of the disease | 9 |
| 4.5.2 Bacteriological status | 9 |
| 4.5.3 Previous treatment history | 10 |
| 4.6 Flow chart for diagnosis of patients | 12 |
| 4.7 Diagnosis of extra-pulmonary TB in adults | 13 |
| 4.7.1 Features and diagnostic approach of EPTB | 13 |

### 5. Treatment of tuberculosis

| 5.1 The role treatment in the control of Tuberculosis | 16 |
| 5.2 Aims of treatment | 17 |
| 5.3 Basic Principles of Treatment | 17 |
| 5.4 Fixed dose combination (FDC) | 17 |
5.5 Standardized Regimens
  5.5.1 Treatment phases
  5.5.2 Standardized treatment regimens for each diagnostic category
5.6 Doses of FDC tablets
5.7 Start of Treatment
5.8 Adherence to treatment
5.9 Ambulatory versus hospital treatment
5.10 DOT providers
5.11 Methods of DOT/Flow chart: Steps for DOT
5.12 Drug supplies to DOT providers
5.13 Regularity of treatment
5.14 Follow-up of treatment
  5.14.1 New smear positive patients
  5.14.2 Retreatment smear-positive patients
  5.14.3 Smear negative and extra-pulmonary patients
5.15 Actions in case of interruption of TB treatment
5.16 Drug reactions
5.17 Treatment outcome
5.18 Referral and transfer of patients
5.19 Treatment of Tuberculosis in special conditions
5.15.1 New smear positive patients
5.15.2 Retreatment smear-positive patients
5.15.3 Smear negative and extra-pulmonary patients
5.16 Drug reactions
5.17 Treatment outcome
5.18 Referral and transfer of patients
5.19 Treatment of Tuberculosis in special conditions

6. Tuberculosis in children
  6.1 Background
  6.2 Clinical spectrum of childhood TB
  6.3 Diagnosis of Tuberculosis in children
  6.4 Treatment of tuberculosis in children
  6.5 Miliary TB in children
  6.6 Tuberculosis meningitis in children
  6.7 Chemoprophylaxis for children
  6.8 BCG vaccination

7. Recording and reporting system
  7.1 Tuberculosis Treatment card
  7.2 Tuberculosis Identity card
  7.3 Tuberculosis Treatment Register
  7.4 Tuberculosis Laboratory Register
  7.5 Request Form for Sputum Examination
  7.6 Tuberculosis Culture/Sensitivity Test Request Form
  7.7 Tuberculosis Referral/Transfer Form
  7.8 Requisition Form for Drugs
  7.9 Absentee Tracing Form
  7.10 Quarterly Report on Case Finding of Tuberculosis
  7.11 Quarterly Report on Treatment Results
  7.12 Quarterly Report on Sputum Conversion at 2/3 months of smear positive pulmonary tuberculosis cases
  7.13 Quarterly Report on Lab. Findings of Tuberculosis
  7.14 Laboratory Request Form
  7.15 Times of Preparation of Reports
### 8. SUPERVISION, MONITORING AND EVALUATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1 Supervision</td>
<td>41-43</td>
</tr>
<tr>
<td>8.2 Monitoring</td>
<td>43-44</td>
</tr>
<tr>
<td>8.3 Evaluation</td>
<td>44</td>
</tr>
</tbody>
</table>

### 9. Supply of drugs, laboratory supplies and documentation materials

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.1 Requirement of drugs</td>
<td>45</td>
</tr>
<tr>
<td>9.2 Requirement of Laboratory Consumables</td>
<td>45</td>
</tr>
<tr>
<td>9.3 Requirement of Documentation materials</td>
<td>46</td>
</tr>
<tr>
<td>9.4 Storage of drugs and supplies</td>
<td>46</td>
</tr>
<tr>
<td>9.5 Issuance of Drugs and Supplies</td>
<td>46</td>
</tr>
<tr>
<td>9.6 Monitoring and Supervision of Stores</td>
<td>46</td>
</tr>
</tbody>
</table>

### 10. Drug-Resistant-TB

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.1 Definition and causes of multidrug-resistant tuberculosis</td>
<td>48</td>
</tr>
<tr>
<td>10.2 Addressing the sources of drug-resistant TB</td>
<td>48</td>
</tr>
<tr>
<td>10.3 Types of drug resistance</td>
<td>49</td>
</tr>
<tr>
<td>10.4 Magnitude of MDR-TB in Bangladesh</td>
<td>49</td>
</tr>
<tr>
<td>10.5 The operational manual</td>
<td>50</td>
</tr>
</tbody>
</table>

### 11. Infection Control

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.1 Components of Infection Control</td>
<td>52</td>
</tr>
<tr>
<td>11.2 Essential Actions for Effective TB Infection Control Safety without stigma</td>
<td>52</td>
</tr>
</tbody>
</table>

### 12. TB-HIV Co-Infection

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.1 Definition: TB/HIV co infection denotes two diseases in one body</td>
<td>56</td>
</tr>
<tr>
<td>12.2 Goal of TB/HIV strategy</td>
<td>56</td>
</tr>
<tr>
<td>12.3 objectives of TB/HIV strategy</td>
<td>56</td>
</tr>
<tr>
<td>12.4 Strategies to achieve the goal and objectives</td>
<td>56</td>
</tr>
<tr>
<td>12.5 Strategy for implementation</td>
<td>57</td>
</tr>
<tr>
<td>12.6 Criteria for TB/HIV Referral</td>
<td>57</td>
</tr>
<tr>
<td>12.7 Mechanism for TB/HIV Referral</td>
<td>57</td>
</tr>
<tr>
<td>12.8 Diagnosis and Management of TB/HIV Co-infection</td>
<td>58</td>
</tr>
<tr>
<td>12.9 Monitoring, Supervision and Reporting</td>
<td>58</td>
</tr>
</tbody>
</table>

### 13. Public-Private Mix (PPM) For TB Control

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.1 The PPM approach for TB Control in Bangladesh</td>
<td>59</td>
</tr>
<tr>
<td>13.2 Current and Potential Providers for PPM</td>
<td>59</td>
</tr>
<tr>
<td>13.3 Roles of Diverse PPM Partners</td>
<td>60</td>
</tr>
</tbody>
</table>

### 14. Advocacy, Communication And Social Mobilization

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 15. Annex

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annex-1 : Job Description</td>
<td>62</td>
</tr>
<tr>
<td>Annex-2 : TB Form</td>
<td>70</td>
</tr>
<tr>
<td>Annex-3 : Supervision Check List</td>
<td>81</td>
</tr>
<tr>
<td>Annex-4 : Drug needed for the different categories of patients</td>
<td>85</td>
</tr>
<tr>
<td>Annex-5 : Laboratory Request Form</td>
<td>86</td>
</tr>
</tbody>
</table>
Abbreviations:
AFB= Acid Fast Bacilli
AHI= Assistant Health Inspector
ACSM= Advocasy, Communication and Social Mobilization
BRAC= Bangladesh Rural Advancement Committee
BCC= Behavioral Change Communication
CDC= Communicable Disease Control
CNS= Central Nervous System
CHW= Community Health Worker
DGHS= Directorate General of Health Services
DOT= Directly Observed Treatment
DOTS= Directly Observed Treatment Short Course
DPM= Deputy Program Manager
EPTB= Extra- Pulmonary Tuberculosis
ESP= Essential Service Packages
FDC= Fixed Dose Combination
HA= Health Assistant
HRD= Human Resource Development
HI= Health Inspector
HE= Health Educator
HIV= Human Immuno-deficiency Virus
HPSP= Health and Population Sector Program
HNPSPP= Health, Nutrition and Population Sector Program
HW= Health Worker
IUATLD= International Union Against Tuberculosis and Lung Disease (UNION)
MDR-TB= Multi Drug Resistant–Tuberculosis
MOHFW= Ministry of Health and Family Welfare
MT= Mantoux test
NGO= Non-Government Organization
NTP= National Tuberculosis Control Program
PM= Program Manager
PHC= Primary Health Care
PTB= Pulmonary Tuberculosis
PPM= Public Private Mix
PO= Program Organizer
TB = Tuberculosis
TB DRUGS= Tuberculosis drugs
E= Ethambutol
H= Isoniazid
R= Rifampicin
S= Streptomycin
Z= Pyrazinamide
SCC= Short Course Chemotherapy
TBM= Tubercular Meningitis
TLCA= Tuberculosis and Leprosy Control Assistant
UHC = Upazila Health Complex
UDRUGS= Upazila Health and Family Planning Officer
VD= Village Doctors
WHO= World Health Organization
1. INTRODUCTION

1.1 Background

Tuberculosis (TB) is a major public health problem in Bangladesh since long. Estimates suggest that daily about 880 new TB cases and 176 TB deaths occur in the country.

Nearly one-third of the global population, i.e. two billion people, is infected with *Mycobacterium tuberculosis* and thus at risk of developing the disease. More than nine million people develop active TB every year and about two million die. More than 90% of global TB cases and deaths occur in the developing world, where 75% of cases are in the most economically productive age group (15-54 years).\(^1\)

In 1993 the World Health Organization (WHO) declared TB as a global emergency and recommended a standard strategy for control of the disease known as “DOTS” or Directly Observed Treatment, Short course.

Under the Mycobacterial Disease Control (MBDC) Directorate of the Directorate-General of Health Services (DGHS), the National Tuberculosis Control Programme (NTP) adopted the DOTS strategy during the Fourth Population and Health Plan (1992-98) under the project “Further Development of TB and Leprosy Control Services”. The NTP started its field implementation in November 1993 in four thanas (upazilas) and progressively expanded to cover all upazilas by June 1998. NGO partners were involved from the inception of DOTS in the country. In July 1998, the NTP was integrated into the Communicable Disease Control component of the Essential Services Package under the Health and Population Sector Program (HPSP). In 2003, HPSP was renamed “Health, Nutrition and Population Sector Program” (HN PSP) and tuberculosis control is recognized as one of the priorities in HNPSP.

From 2002, NTP expanded its collaboration with other public and private health care providers. The DOTS strategy was rolled out to all metropolitan cities in collaboration with different NGOs. Administrative DOTS coverage is considered universal in the country.

The Government of Bangladesh, together with its many and diverse partners from the public and private sectors, is committed to further strengthen the TB control programme. It has adopted the Stop TB strategy in 2006, which includes and builds on the DOTS strategy. This is done with a view of sustaining the achievements of the past years and reaching the TB control targets linked to the Millennium Development Goals (MDGs).

1.2 Vision Statement of the National TB Control Programme

Tuberculosis is no more a public health problem in Bangladesh.

---

\(^1\) Source: Global Tuberculosis Report (2008)
1.3 Mission Statement of the National TB Control Programme

The NTP aims to strengthen TB control efforts through establishing effective partnerships, mobilizing necessary resources and ensuring quality diagnostic and treatment services under DOTS strategy. It strives to make services equally available to all people in Bangladesh irrespective of age, sex, religion, ethnicity, social status or race.

1.4 Goal of Tuberculosis Control

The overall goal of TB control is to reduce morbidity, mortality and transmission of TB until it is no longer a public health problem.

1.5 Objectives of the National Tuberculosis Control Programme

The objectives of NTP are:

- To sustain the global targets of achieving at least 70% case detection and 85% treatment success among smear-positive TB cases under DOTS for the country as a whole;
  in order to then
- Reach the interim target of halving the TB death and TB prevalence rates by 2010 towards achieving a reduction of incidence of TB, as stated under the MDGs (2015).

1.6 Strategies for Control of Tuberculosis

DOTS as internationally recommended are the most effective strategy available for controlling the TB epidemic. The NTP of Bangladesh follows this strategy to achieve its objectives and targets. DOTS have the following five components:

- Political commitment with increased and sustained financing;
- Case detection through quality-assured bacteriology;
- Standardized treatment with supervision and patient support;
- An effective drug supply and management system;
- Monitoring and evaluation system and impact measurement.

In order to achieve the TB targets set under the Millennium Development Goals, Bangladesh is in the process of expanding the scope of services in line with the Stop TB strategy. The Stop TB strategy consists of six elements:

- Pursue high quality DOTS expansion and enhancement;
- Address TB/HIV, MDR/XDR-TB and other challenges;
- Contribute to health systems strengthening;
- Engage all care providers;
- Empower people with TB, and communities;
- Enable and promote research.
1.7 Activities of NTP

To achieve the objectives, the main activities of the NTP are:

- Developing policies, strategies and guidelines for TB control
- Planning and budgeting for TB control activities
- Developing human resources TB control including training
- Promoting early detection of smear-positive patients at all levels of the health services
- Implementing quality assurance for smear microscopy
- Diagnosing smear-negative, extra-pulmonary and childhood TB cases
- Ensuring Directly Observed Treatment (DOT) through community participation and involvement of government and nongovernmental health care providers.
- Ensuring uninterrupted supply of drugs, laboratory equipments and consumables and other logistics
- Implementing of standardized recording and reporting systems
- Involving academic medical institutes and hospitals, private practitioners, special services like prisons, defense, industries and other corporate sectors in the NTP
- Strengthening cooperation and collaboration between the government of Bangladesh and nongovernmental organizations (NGOs) involved in control of tuberculosis
- Conducting regular supervisions, monitoring and evaluation of NTP thus measuring impact of interventions
- Ensuring programmatic management of Drug Resistant TB
- Establishing linkage for management of TB-HIV co infection
- Intersectoral and Interministerial collaboration
- Maintaining liaison with development partners and establishing intersectoral and interministerial collaboration
- Carrying out operational research related to TB control

2. GENERAL INFORMATION ABOUT TUBERCULOSIS

2.1 Definition of tuberculosis

Tuberculosis is an infectious disease, caused by the bacillus called *Mycobacterium tuberculosis*. The bacilli usually enter the body by inhalation through the lungs and spread to other parts of the body via the blood stream, the lymphatic system, or through direct extension to other organs.

Tuberculosis of the lungs or pulmonary tuberculosis is the most common form of TB and occurs in about 80% of cases. Extra-pulmonary tuberculosis can affect any part of the body other than lungs.

2.2 Difference between TB infection and TB disease

2.2.1 TB infection

TB spreads through droplet infection. TB bacilli stay suspended in the air as droplets. Healthy people become infected with TB through inhalation of the droplets containing TB
bacilli. Around 90% of the infected people do not progress to TB disease because of their immunity. Around 10% of the infected people develop TB disease in their lifetime.

People with TB infection usually (1) do not have symptoms; (2) do not feel sick (3) cannot spread TB to others; or (4) have a positive skin test (Mantoux test).

2.2.2 TB disease

Around 10% of the people infected with TB bacilli may progress to TB disease in their lifetime. TB bacilli multiply in their lungs or other organs and produce the symptoms and signs. Around 5% of the infected people develop TB disease within months or years and the remaining in their old age that is known as reactivation of the disease. TB disease means TB infection plus presence of signs and symptoms of TB.

2.3 Spread of tuberculosis bacilli

Patients with pulmonary tuberculosis who cough up TB bacilli through coughing, sneezing and spitting are the main source of TB infection. Presence of TB bacilli in the sputum can be identified on microscopic examination of sputum specimens. Such patients whose sputum contains TB bacilli are known as smear-positive cases.

If the bacilli cannot be identified on microscopy examination of sputum specimens of pulmonary cases, the patients are known as smear-negative cases. In contrast to smear-positive cases, smear-negative cases are less infectious and the disease is usually less severe. Extra-pulmonary cases are almost never infectious, unless they have pulmonary tuberculosis as well.

An infectious tuberculosis patient expels TB bacilli into the air through tiny droplets during coughing and sneezing. These droplets dry quickly, become droplet nuclei carrying the bacilli, and may remain suspended in the air for several hours. Infection occurs if the inhaled bacilli in these droplet nuclei enter and settle in the lungs of a healthy person and begin to multiply.

The degree of exposure is extensive for those who are in close and prolonged contact with an infectious case (i.e. persons who are living in the same household with infectious TB cases).

The bacilli are rapidly destroyed by exposure to sunlight and their concentration in the air is reduced by good ventilation.

2.4 Development of tuberculosis

If the body immune mechanism is not seriously compromised, approximately 90% of the infected cases will not develop tuberculosis disease; in this case the bacilli usually remain dormant within the body. The remaining 10% of infected individuals will subsequently develop disease, half of them shortly after infection, the other half later in their life.
The job descriptions of the different medical and paramedical staff involved in the NTP are given in Annex 1 A-H.
4. CASE FINDING AND DIAGNOSIS OF TUBERCULOSIS

4.1 Signs and symptoms of TB

The highest priority for TB control is identification and successful treatment of patients who are suffering from smear-positive pulmonary TB.

Pulmonary TB should be suspected in a person who presents with persistent cough for three weeks or more, with or without production of sputum despite the administration of a non-specific antibiotic.

Often a patient with pulmonary TB has one or more of the following symptoms in addition to cough:

- Respiratory symptoms: shortness of breath, chest pain, coughing up of blood
- General symptoms: loss of weight, loss of appetite, fever, night sweats

Sputum microscopy should always be requested for a patient, who has cough for three weeks or longer, even in the absence of any other symptom.

Signs and symptoms of extra-pulmonary TB depend on the site involved. Most common examples are:

- TB lymph adenitis: swelling of lymph nodes
- Pleural effusion: fever, chest pain, shortness of breath
- TB arthritis: pain and swelling of joints
- TB of the spine: radiological findings with or without loss of function
- Meningitis: headache, fever, stiffness of neck and subsequent mental confusion

The diagnosis of extra-pulmonary TB should always be made by a graduate physician or specialist and often requires special examinations such as X-ray examinations, biopsies, FNAC, etc.

4.2 Method of case finding

The most important method of case finding either is identification of suspects at a health facility, on their own initiative or referred by another health facility, health worker, community volunteer, etc.

Patients diagnosed with any form of TB should always be asked whether there is anybody living in the same house that has chronic cough and be encouraged to bring or send that person to the health facility for sputum examination.

4.3 Organization of case finding by medical staff and non-medical individuals

4.3.1 By medical staff

Selection of people symptomatic for TB referred by different health providers and volunteers and arranging for examination of their sputum is the responsibility of medical
doctors of governmental health facilities and NGO facilities involved in the NTP. In addition, case registration is the responsibility of medical doctors of academic institutes, prisons, defense, corporate sectors and private practitioners directly collaborating with the NTP or through partner NGOs.

4.3.2 By non-medical persons

Community participation plays an important role in identification of TB suspects and motivating them to have their sputum examined or to visit a health facility for diagnosis.

Non-medical community members include the following persons:

- Village doctors
- Cured patients and patients under treatment
- Shasthya shebikas or volunteers
- Other important persons in the community such as religious and village leaders, political leaders, members of union councils, school teachers and persons who have close communication with women in the community.

4.4 Diagnosis

4.4.1 Tools for diagnosis of TB

**Sputum smear examination**

The most cost-effective tool for screening pulmonary TB suspects is microscopy examination of their sputum by the Ziehl-Neelsen method. Over 65% of pulmonary TB patients are smear-positive and will be detected by this method. In the remaining pulmonary TB patients, the number of bacilli in their sputum is too low to be detected through this method. Sputum examination is the most reliable procedure for diagnosis of TB.

**Radiological (X-ray) examination of the lungs**

Chest X-Ray findings do not specifically indicate pulmonary tuberculosis because there are other chest diseases which may show the same changes on X-ray. Chest X-ray findings suggestive of pulmonary tuberculosis in patients with smear-negative microscopy should always be supported by clinical findings. A qualified physician should decide on the diagnosis of TB.

**Tuberculin skin test (Mantoux Test)**

This test is only used for supporting TB diagnosis in young children. (see details in children tuberculosis section)

In populations with a high TB prevalence, the tuberculin skin test is of little value in the diagnosis of TB disease in adults. A positive tuberculin skin test does not by itself differentiate *M. tuberculosis* infection from TB disease. Previous exposure to environmental mycobacteria may also result in a false-positive test result. With increasing age an increasing percentage of the population will have been infected with *M. tuberculosis* (almost
100% at the age of 40-50 years) and 90% of them will not have developed TB disease. Hence, diagnosis of TB based on Mantoux test will lead to over-diagnosis of many patients. Conversely, the tuberculin skin test result may be negative, even when the patient has TB. Conditions often associated with a false-negative tuberculin skin test include severe malnutrition, miliary TB, HIV infection and other immuno-compromised condition.

**Culture of TB bacilli**

Culture is more sensitive than smear microscopy, detecting a higher proportion of patients among suspects. If resources permit and adequate, quality-assured laboratory facilities are available, culture should be included in the algorithm for evaluating patients with negative sputum smears. However, it takes about six weeks to provide a definite result, and is not accessible to most patients. Therefore, it is unsuitable as routine procedure. The probability of finding acid-fast bacilli in sputum smears by microscopy is directly related to the concentrations of bacilli in the sputum. Sputum microscopy is likely to be positive when there are at least 10 000 organisms per ml of sputum. At concentrations below 1000 organisms per ml of the sputum, the chance of observing acid-fast bacilli in a smear is less than 10%. In contrast, a properly performed culture can detect organism even concentrations below 100 organisms per ml.

**FNAC and Biopsy**

These are special tests performed to confirm extra pulmonary TB to be referred to concerned specialists.

**4.4.2 Examination of sputum specimens**

Microscopy should be performed on three sputum specimens, as follows:

- “On-the-spot” specimen: the first specimen is collected on the spot when a patient is identified as a pulmonary TB suspect (Spot-I specimen),
- Early morning specimen: the patient is given a sputum container to collect the second specimen, at home on the following morning (Early Morning Specimen),
- A second “on-the-spot” specimen: the third specimen is collected when the patient returns to the health facility with the early morning specimen (Spot-II specimen).

The responsible medical officer or paramedic/laboratory technologist should provide clear instruction to the patient on how to collect the sputum: in the open air and as far as possible away from other people. If the patient attends a centre where microscopy facilities are available, he/she should either be instructed to bring the specimens to the responsible medical officer or paramedic or directly to the laboratory. If the patient attends a centre without microscopy facility, the responsible staff should ensure that the three sputum specimens are brought within five days after collection to the microscopy centre.

To increase accessibility to diagnostic services, outreach sputum collection centres are organized by NGOs with support of government field staff at Union Health and Family Welfare Centres or other suitable places. If the patient attends an outreach center, he/she should be instructed one day earlier to bring the two sputum specimens (evening and early morning sputum samples) and produce another specimen on the spot.
4.5 Case definitions

Diagnosis of TB should be followed by specification of the type of TB or case definition.

Case definition takes the following into account:
- The anatomical site of disease (pulmonary or extra-pulmonary)
- The bacteriological results (smear-positive or smear-negative)
- The history of previous treatment (new or retreatment)

Case definition is necessary for:
- Correct choice of standard regimen
- Correct patient registration and reporting
- Cohort analysis
- Determining trends in the proportions of the different types of patients

4.5.1 Anatomical site of the disease

The categories by anatomical site are **pulmonary** and **extra-pulmonary TB**.

**Pulmonary TB**

Pulmonary TB refers to disease affecting the lung parenchyma.

**Extra-pulmonary TB**

Extra-pulmonary TB refers to tuberculosis of organs other than the lungs only. TB may affect any organ or tissue. Examples are: mediastinal and/or hilar lymph nodes, larynx, cervical lymph nodes, pleurae, meninges, central nervous system, spine, bones and joints, kidneys, pericardium, intestines, peritoneum and skin.

In miliary TB, there is acute haematogenous spread. Miliary tuberculosis is classified as pulmonary TB because there are lesions in the lungs.

Patients diagnosed with both pulmonary and extra-pulmonary TB should be classified as pulmonary TB.

4.5.2 Bacteriological status

Defining the smear status in pulmonary cases is important to:

- Identify smear-positive cases. These patients are the most infectious cases and usually have higher mortality;
- Record, report and evaluate programme performance (smear-positive cases are the cases for which bacteriological monitoring of treatment progress is most practicable.

Pulmonary TB is divided into smear-positive and smear-negative pulmonary cases. Smear-positive cases represent 65-70% of all pulmonary cases and more than 50% of all TB cases.
4.5.3 Previous treatment history

The treatment history is very important for proper categorization of the patient subsequently choosing the correct regimen.

Table 1: Case definition by site and bacteriological status in adults

<table>
<thead>
<tr>
<th>Case classification</th>
<th>Definition</th>
</tr>
</thead>
</table>
| Pulmonary smear-positive TB (PTB+) | • A patient with at least two sputum specimens positive for AFB;  
  or  
  • A patient with only one sputum specimen positive for AFB and chest radiological X-ray abnormalities consistent with active TB and diagnosis made by a graduate physician;  
  or  
  • A patient with only one sputum specimen positive for AFB and a culture positive for *M. tuberculosis* |
| Pulmonary smear-negative (PTB-) | • A patient with symptoms suggestive of TB with three sputum specimens negative for AFB;  
  and  
  • Persisting symptoms after a course of antibiotics;  
  and  
  • Again three negative sputum specimens for AFB during repeat sputum examination;  
  and  
  • Chest X-ray abnormalities consistent with active TB;  
  and  
  • Diagnosis made by a graduate physician |
<p>| Extra-pulmonary TB (EPTB) | • A patient with TB of organs other than the lungs as confirmed by a qualified physician |</p>
<table>
<thead>
<tr>
<th>Case classification</th>
<th>Definition</th>
</tr>
</thead>
</table>
| **New**             | - A patient who has never received anti-TB drugs;  
                      or  
                      - A patient who received anti-TB drugs for less than one month |
| **Relapse**         | - A patient previously treated for TB who has been declared “cured” or “treatment completed” and is diagnosed with bacteriologically positive (smear or culture) tuberculosis |
| **Treatment failure** | - A patient who, while on treatment, remained smear-positive or became smear-positive again at five months or more after the start of treatment  
                      or  
                      - A patient who was initially smear-negative and was found smear-positive at the end of the second month of treatment |
| **Treatment after default** | - A patient who returns to treatment after completion of at least one month of treatment and with a positive bacteriology, following interruption of treatment for two or more months |
| **Transfer in**     | - A patient already registered for treatment in a DOTS centre and who is subsequently transferred to another registration unit |
| **Chronic**         | - A patient who remained smear-positive after completing a directly observed re-treatment regimen |
| **Other (s)**       | - All cases that do not fit the above definitions. |
4.6 Flow chart for diagnosis and follow up of pulmonary TB

Cough for 3 weeks or more

3 sputum smear exams (Day 1-spot sputum
Day 2- early morning sputum
And spot sputum)

3 SMEARS +VE
OR 2 SMEARS +VE
AND 1 SMEAR -VE

*START CAT. I or II
TREATMENT

3 SMEARS +VE
OR 2 SMEARS +VE
AND 1 SMEAR -VE

*START CAT. I or II
TREATMENT

1 SMEAR +VE and
2 SMEAR-VE or
DOUBTFUL SMEARS

REPEAT 3 SMEARS

NEGATIVE

POSITIVE
START CAT. I or II *

MAKE CHEST X-RAY

X-RAY
POSITIVE (NEED PHYSICIAN
JUDGMENT)

*START CAT. I or II
TREATMENT

X-RAY
NEGATIVE

NON TB CASE

REQUEST FOR
FOLLOW-UP
VISIT

X-RAY
POSITIVE

*START CAT. I or II
TREATMENT

X-RAY
NEGATIVE

NEGATIVE

MAKE CHEST X-RAY

POSITIVE
START CAT. I or II *

NEGATIVE

NON TB CASE

**Exclude Clarithromycin, Quinolones, Amoxycyclavulanate

Previous history of treatment > 1 month: CAT II
4.7 Diagnosis of extra-pulmonary TB in adults

Extra-pulmonary TB can occur at any age and can involve any organ. Many patients with EPTB may also suffer from pulmonary TB.

Definitive diagnosis of extra pulmonary TB is often difficult. Diagnosis may be presumptive, provided other conditions mimicking tuberculosis can be excluded. Patients usually present with constitutional features (fever, night sweats, weight loss) and local features related to the site of disease. The degree of certainty of diagnosis may depend on the availability of diagnostic tools, e.g. X-ray, ultrasound, FNAC, biopsy, etc.

Diagnose the case as EPTB using the following diagnostic tools:

<table>
<thead>
<tr>
<th>Diagnostic Tools</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Smear and/or culture for AFB of bodily fluids: pleural fluid, pericardial fluid, ascetic fluid (laparoscopic), cerebrospinal fluid (by lumbar puncture), urine, aspirate (FNAC) from any solid organ e.g. lymph node, spine, epididymis</td>
</tr>
<tr>
<td>✓ Histopathological examination (biopsy) – finding of caseating granuloma in the biopsy material obtained from body tissues such as lymph node, peritoneum (laparoscopic), synovium, spine, bone, liver, spleen, genital tract, etc.</td>
</tr>
<tr>
<td>✓ X-ray of involved structure, e.g. lung, spine, bone, joint, adrenal gland</td>
</tr>
<tr>
<td>✓ Biochemical test, e.g. exudate (low sugar and high protein)</td>
</tr>
<tr>
<td>✓ Cytological examination of effusions, ascites, CSF fluid, etc.</td>
</tr>
<tr>
<td>✓ Tuberculin test.</td>
</tr>
</tbody>
</table>

4.7.1 Features and diagnostic approach of EPTB

**Tuberculosis lymphadenopathy**

The lymph nodes most commonly involved are the cervical nodes. Other sites may also be involved including submandibular, supraclavicular, inguinal or axillary nodes. Involvement of lymph nodes may result from direct extension of infection or from haematogenous spread.

The usual course of lymph node disease is as follows. Initially they are firm and discrete, later become fluctuant and matted together followed by abscess formation. The skin may then breakdown leading to chronic sinus formation and ultimately healing with scarring.

Diagnosis is based on FNAC (smears for AFB, cultures for AFB, caseation); biopsy (caseating granuloma); AFB staining and AFB culture.

**Miliary (disseminated) TB**

Miliary TB results from widespread bloodborne dissemination of TB bacilli. Although in children it is often the consequence of a recent (primary) infection, in adults it may be due to either recent infection or reactivation of old disseminated foci.
Patients present with constitutional features rather than respiratory symptoms. They may have hepatosplenomegaly and choroidal tubercles on fundoscopy. Often the presentation is associated with fever of unknown origin and wasting may be marked. A rare presentation seen in the elderly is cryptic miliary tuberculosis which has a chronic course and remains undiagnosed unless there is high degree of suspicion. An acute septicemic form, non-reactive miliary tuberculosis occurs very rarely and is due to massive hematogenous spread of tubercle bacilli.

Diagnosis is based on chest X-ray. It shows diffuse, uniformly distributed, small miliary shadows. "Miliary" means "like small millet seeds". Various hematological abnormalities may be seen including anemia, leucopenia, neutrophilic leukocytosis and leukemoid blood reactions. Liver function tests may be abnormal. Bacteriological confirmation (smear or culture) is sometimes possible from sputum, cerebrospinal fluid, bone marrow, liver or blood. Granulomas are evident in liver or bone marrow biopsy specimen from many patients. Bronchoalveolar lavage is more likely to permit bacteriological confirmation.

**Tuberculous serous effusions (pleural, pericardial, ascites)**

The presentation is usually with constitutional and local features.

Microscopy of the aspirate from tuberculous serous effusions rarely shows AFB because the fluid forms as an inflammatory reaction to TB lesions in the serous membrane. TB culture, even if available, is of no immediate help. The white cell content is variable, usually with predominant lymphocytes and monocytes. The aspirate is an exudate (i.e. protein content is more than 30 g/l; it is easily determined by leaving the aspirate standing and if "spider clots" develop in the specimen, it is an exudates). Interpret with caution the laboratory result of protein concentration in any aspirated fluid. If there has been a delay in laboratory analysis, a protein clot may have formed in the sample. The laboratory result may then be falsely low.

Tuberculous pleural effusion: The clinical and chest X-ray diagnosis of a pleural effusion is straightforward. Ultrasound can confirm the presence of fluid in the pleural space in case of doubt. Always perform diagnostic pleural aspiration if a patient has a pleural effusion. The fluid is usually straw-colored. The white cell count is usually high with predominant lymphocytes. Occasionally the fluid is blood-stained. The presence of pus on aspiration indicates an empyema (purulent effusion). If facilities are available, closed pleural biopsy using an Abrams needle is useful for histological diagnosis. Since the distribution of TB lesions in the pleura is patchy, the diagnostic yield of closed pleural biopsy is about 75%. Multiple biopsies increase the diagnostic yield. A small open pleural biopsy increases the yield even further.

Tuberculous pericardial effusion: The diagnosis usually rests on suggestive constitutional and cardiovascular features and investigation findings (ECG, chest X-ray and echocardiography).

Tuberculous ascites: Ascites results from peritoneal TB. Routes of spread of TB to the peritoneum include the following: a) from tuberculous mesenteric lymph nodes; b) from intestinal TB (pulmonary TB patients may develop intestinal ulcers and fistulae as a result of swallowing infected sputum); c) blood-borne. Patients present with constitutional features
and ascites. There may be palpable abdominal masses (mesenteric lymph nodes). Aspirated fluid is exudative with high protein content and leucocytosis with predominantly lymphocytes. The yield of direct smear and culture for AFB is relatively low; culture of a large volume ascitic fluid can increase the yield. Ultrasound may show features consistent with TB, including enlarged mesenteric or retroperitoneal lymph nodes. Definitive diagnosis rests on a peritoneal biopsy. Blind percutaneous needle biopsy of the peritoneum has a low pick-up rate and a high complication rate. In experienced hands, laparoscopy under local anesthetic has a high pick-up rate. Laparoscopy enables direct visualization and biopsy of peritoneal TB lesions. Laparotomy will confirm the diagnosis in nearly every case but is too invasive for routine use.

**Gastro-intestinal TB**

Any portion of the gastrointestinal tract may be affected by tuberculosis. The terminal ileum and caecum are the sites most commonly involved. Abdominal pain (at times similar to that of appendicitis), chronic diarrhea, subacute obstruction, hematochezia and a right iliac fossa mass are common findings at presentation. Fever, weight loss and night sweats are also frequent. A ‘doughy abdomen’ due to extensive intra-abdominal inflammation may also be detected. Diagnosis rests on barium examination of the small and large intestine or on colonoscopy.

**Spinal TB (Pott’s disease)**

The sites most commonly involved are the lower thoracic vertebrae (with T-10 being the most common) and upper lumbar spine but the cervical spine can also be affected. TB starts in an intervertebral disc and spreads along the anterior and longitudinal ligaments, before involving the adjacent vertebral bodies. With advanced disease, collapse of vertebral bodies’ results in kyphosis (gibbus). A para-vertebral cold abscess may also form. And this may track to sites such as the lower thoracic case or below the inguinal ligament (Psoas abscess). Plain X-ray of the spine is usually diagnostic. The typical appearance is erosion of the anterior edges of the superior and inferior borders of adjacent vertebral bodies. The disc space is narrowed. CT scan or MRI reveals the lesions more correctly. Aspiration of the abscess or bone biopsy confirms the tuberculous etiology by histopathology and culture. The main differential diagnoses are malignancy and pyogenic spinal infections. Malignant deposits in the spine tend to erode the pedicles and spinal bodies, leaving the disc intact. Pyogenic infection tends to be more acute than TB, with more severe pain.

**Joint TB**

Weight bearing joints are mostly affected. Tuberculosis of the hip joints causes pain and limping. TB of the knee produces pain and swelling. A history of previous trauma is often elicited. Systemic symptoms are present in about half of the patients. Pulmonary TB is detected in approximately half of these patients. Radiological abnormalities include bone erosions, joint space narrowing, and ultimately joint destruction. Diagnosis requires synovial biopsy.
**Genito-urinary TB**

Tuberculosis can involve any part of genitourinary tract. It is usually due to hematogenous seedling following primary infection. Local symptoms predominate. Urinary frequency, dysuria, hematuria, and loin pain are common presentations. However patient may be asymptomatic and the disease discovered after severe destructive lesions of the kidneys have developed. Urinalysis gives abnormal result in 90% of cases, revealing pyuria and hematuria. Sterile pyuria first raises the suspicion of renal tuberculosis. An intravenous pyelography helps in the diagnosis. Calcification and ureteric stricture are suggestive findings. AFB from centrifuge urine specimen helps in diagnosis. Culture of three morning urine specimens yields a definitive diagnosis in nearly 90% cases. Severe ureteric strictures may lead to hydronephrosis and renal damage.

Genital tuberculosis is more common in female than in male patients. In female patients, it affects the fallopian tubes and endometrium and may cause infertility, pelvic pain and menstrual irregularities. Diagnosis requires biopsy and/or culture of specimens obtained by dilatation and curettage (D and C). In male patients, tuberculosis preferentially affects the epididymis (producing a slight tender mass), orchitis and prostatitis may also develop. In almost half of cases of genitourinary tuberculosis, urinary tract disease is also present.

**Hepatic/Splenic TB**

Disseminated TB may involve the liver or spleen and can cause diagnostic confusion. Solitary or multiple abscesses may develop. Ultrasound or CT scan and guided FNAC give diagnosis in most of the cases.

**Less common extra-pulmonary forms**

Tuberculosis may cause chorioretinitis, uveitis, panophthalmitis, phlyctenular conjunctivitis. In the nasopharynx, tuberculosis may simulate Wegner’s granulomatosis. Cutaneous manifestations of tuberculosis include primary infection due to direct inoculation, abscess and chronic ulcers, scrofuloderma, lupus vulgaris, miliary lesions, and erythema nodosum. Adrenal tuberculosis is a manifestation of advanced disease presenting as sign of adrenal insufficiency.

**CNS tuberculosis**

As described under children tuberculosis.

5. **TREATMENT OF TUBERCULOSIS**

5.1 The role of treatment in the control of tuberculosis

Treatment and cure of infectious cases of tuberculosis will interrupt transmission of TB infection in the community. Therefore, successful completion of treatment is the most effective way of prevention of TB.
5.2 Aims of treatment

The aims of treating TB are:
- To cure the patient of TB
- To prevent death from active TB or its late effects
- To prevent relapse of TB
- To decrease transmission of TB to others
- To prevent the development of acquired drug resistance

5.3 Basic Principles of TB treatment

The basic principles of good TB treatment are:

a) Right combination of drugs to kill different bacterial populations;

b) Drugs are given for the right duration (several months) to kill the bacilli;

c) Drugs are given in the right dosage to achieve therapeutic but not toxic effect.

5.4 Fixed-dose combinations (FDCs)

Tablets of fixed-dose drug combinations have several advantages over individual drugs:

a) Prescription errors are likely to occur less frequently because dosage recommendations are more straightforward and adjustment of dosage according to patient weight is easier

b) The number of tablets to ingest is smaller and may thus encourage patient’s adherence. A new smear-positive patient of 38-54 kg body weight has to take three tablets of 4-FDC daily during the intensive phase of treatment. In case of loose drugs this would be nine tablets (three R150, one H300, three Z500 and two E400).

c) Drug resistance is less likely to occur; patients swallow all drugs and cannot skip any particular drug

FDCs have the disadvantage that if severe side-effects occur, all drugs have to be stopped and the patient has to continue treatment with single drugs, excluding the drug(s) which might be responsible for the side-effect. In order to manage side effects, 5% of single drugs will be supplied together with FDCs.

5.5 Standardized Regimens

Standardized regimens have the following advantages over individualized prescription of drugs:

- Less risk for drug resistance development due to reduction in prescription errors;
- Better estimates of drug needs, purchasing, distribution and monitoring;
- Facilitate staff training;
- Reduced costs;
Facilitates regular drug supply when patients move from one area to another.

Bangladesh NTP has adopted standardized regimens for new and retreatment cases.

5.5.1 Treatment phases

Effective chemotherapy consists of two phases:

(a) The initial or intensive phase administered daily for two months in new cases and three months in re-treatment cases. The aim of this phase is to rapidly reduce and eliminate the multiplying bacilli without allowing the development of acquired resistance to the prescribed drugs. During the intensive phase, the tubercle bacilli are killed rapidly. The infectious patients quickly become non-infectious (within approximately two weeks).

(b) The continuation phase is essential to eliminate the remaining bacterial population. Drugs administered daily for the rest of the treatment duration according to category.

5.5.2 Standardized treatment regimen for each diagnostic category (Adults)

<table>
<thead>
<tr>
<th>TB diagnostic category</th>
<th>Patient Category</th>
<th>Treatment regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Intensive phase (DAILY)</td>
</tr>
<tr>
<td>I</td>
<td>New smear-positive patients</td>
<td>2(HRZE)</td>
</tr>
<tr>
<td></td>
<td>New smear-negative PTB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extra-pulmonary TB</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Concomitant/associated HIV/AIDS</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>Sputum smear-positive PTB with history of treatment of more than one month</td>
<td>2(HRZE)S / 1(HRZE)</td>
</tr>
<tr>
<td></td>
<td>Relapse</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment failure after Cat. I</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment after default</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
</tr>
</tbody>
</table>

5.6 Dosages of FDC tablets

FDC tablets are composed as follows:

- 4-FDC: rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275 mg
- 2-FDC: rifampicin 150 mg + isoniazid 75 mg
The dosages of FDC tablets for adults are as follows:

**Category I**

<table>
<thead>
<tr>
<th>Pre-treatment weight (kg)</th>
<th>Intensive Phase</th>
<th></th>
<th>Continuation Phase</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Daily (first 2 months)</td>
<td>Daily (Next 4 months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number of 4FDC tablets</td>
<td>Number of 2 FDC tablets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 – 37</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 – 54</td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55 – 70</td>
<td>4</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 70</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Category II**

<table>
<thead>
<tr>
<th>Pre-treatment weight (kg)</th>
<th>Intensive Phase</th>
<th></th>
<th>Continuation Phase</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Daily (first 3 months)</td>
<td>Daily (first 2 months)</td>
<td>Daily (next 5 months)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number of 4- FDC tablets</td>
<td>Injection Streptomycin</td>
<td>Number of 2- FDC tablets</td>
<td>Ethambutol 400mg (Number of tablets)</td>
</tr>
<tr>
<td>30 – 37</td>
<td>2</td>
<td>500mg</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>38 – 54</td>
<td>3</td>
<td>750mg</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>55 – 70</td>
<td>4</td>
<td>1gm*</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>&gt; 70</td>
<td>5</td>
<td>1gm*</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

* The dose of streptomycin should not exceed 750 mg daily after the age of 50 years

**5.7 Start of Treatment**

Treatment should be started as soon as possible after the diagnosis is made. **TREATMENT SHOULD ONLY BE STARTED AFTER A CONFIRMED DIAGNOSIS HAS BEEN MADE.**

The responsible medical officer/graduate physician should categorize the patient. A paramedical staff may fill in the treatment card and register the patient in the TB register and maintain other documents related to diagnosis of the patients.

The first dose of drugs should be given at the respective health facility, where after the patient is referred to the DOT provider (see 5.11). At the time of start of treatment all drugs for the whole course of treatment (intensive and continuation phase) of the respective patient should be ensured. In case of transfer or death of a patient, the remaining drugs should be returned and added to the general stock.

The medical officer or TB manager/supervisor should weekly review and cross check the TB register with the laboratory register to ensure that all patients diagnosed in the laboratory are registered and enrolled for treatment.
Patients who are smear-positive according to the laboratory register but did not begin treatment should be traced within two weeks after the laboratory result is available.

5.8 Adherence to treatment

Patient compliance is a key factor to treatment success. A proportion of patients stop treatment before completion, for various reasons so **strict adherence to treatment should be ensured to cure the patients and prevent the development of drug-resistant TB**.

Directly observed treatment (DOT) is a very important component in the internationally recommended policy package for TB control (DOTS strategy).

DOT means that an observer watches the patient swallowing their drugs, which is essential for completion of treatment and recovery from TB. This ensures that the patient takes the right anti-TB drugs, in the right doses, at the right intervals and for the right period. All patients, irrespective the treatment category, should receive all doses of the anti-TB drugs under DOT.

5.9 Ambulatory versus hospital treatment

Over 95% of the patients can be treated as ambulatory TB cases. Hospitalization itself has little or no effect on the outcome of the treatment except in severe forms of tuberculosis. Hospitalization may be necessary if the patient cannot receive ambulatory treatment under direct observation. In-patient treatment may also be necessary (often only for a short period) for severely ill patients, e.g. tuberculosis with complications viz. severe hemoptysis (bloodstained sputum), spontaneous pneumothorax (air in the inter-pleural space resulting in collapse of the lung) or for those with other associated serious diseases.

5.10 DOT providers

To ensure adherence to treatment, DOT should be provided as conveniently as possible to the patient. This often means as close to the patient’s home or workplace as possible. Patients may wish to attend any of the NTP recognized DOT centres according to patients convenience.

The DOT provider may be a facility- or community-based health worker or a trained and supervised community member. These DOT providers include health assistants (HAs), assistant health inspectors (AHIs), community health workers (CHWs), shasthya shebikas, village doctors, community leaders, cured patients, etc. All non-medical personnel who deliver DOT should be supervised at least monthly.

Medical officers and paramedics in consultation with patients should identify the DOT provider, the name and address of whom should be recorded on the patient's treatment card. The medical officer or paramedic has to ensure that the DOT provider receives the filled-in copy of Treatment Card (TB 01) and Identity Card (TB 02) and drugs at the specific intervals.
5.11 Methods of DOT

The following flow chart shows the decision tree for DOT.

Can the patient come to the treatment center everyday?

- No
- Yes
  - Tell the patient to come daily
  - Give 1 day supply of medicine for weekends and other public holidays

Can the patient come to the Sub Centre (SC)/ Family Welfares Centre (FWC)/ Community Clinic (CC) every day?

- No
- Yes
  - Communicate with the responsible person of the selected center and arrange for DOT
  - Ensure a copy of TB 01 and regular drug supply to the center for that particular patient
  - Confirm attendance on original treatment card (TB 01) kept at the initiating center by the responsible person
  - Ensure attendance of the patient at microscopy center for follow up of sputum examination at specified intervals

Is there a reliable Health Worker / DOT providers?

- No
- Yes
  - Communicate with the health worker/DOT providers and arrange for DOT
  - Training should be ensured to non medical DOT provider before referring the patient to that provider
  - Ensure a copy of TB 01 and regular drug supply (2-4 wks) to the selected DOT provider for that particular patient
  - Confirm attendance of the patient in original treatment card (TB 01) kept at the initiating center by the responsible person
  - Ensure attendance of the patient at microscopy center for follow up of sputum examination at specified intervals
  - Non medical DOT providers should be supervised at least monthly by the initiating centre

Can the patient be admitted to hospital for the intensive phase of Treatment?

- No
- Yes
  - Admit and give DOT

Reinforce any method

5.12 Drug supplies to DOT providers

If DOT is provided at the centre where the patient is registered, the drugs for that patient, for the whole course of the treatment, should be kept at the place which is secure and suitable for drugs in that centre. The paramedic responsible for DOT should be given the drugs for two weeks at a time.
If DOT is provided from a sub-center, where the patient is not registered for treatment or at community level by a health worker / DOT provider drugs needed for two to four weeks should be given at a time to the DOT provider until end of the treatment.

5.13 Regularity of treatment

DOT providers should make sure that the patients swallow the drugs according to prescription. They should organize tracing of absentees and prevent patients from becoming defaulters.

If a Category I and II patient misses consecutive three doses of the treatment he/she must be traced immediately to resume DOT without delay.

To ensure easy tracing of patients the detailed address should be filled in the Tuberculosis Treatment Card and TB Register. (Mobile number should be included if available with the patient).

5.14 Follow-up of treatment

In order to evaluate the result of treatment, sputum smear examinations should be performed at defined intervals.

5.14.1 New smear positive patients

One sputum specimen should be examined at the end of month 2, 5 and 6 after the start of treatment. The sputum at six months can also be collected during the last two weeks of treatment.

Patients whose sputum is positive at month 2 should continue the intensive phase for one more month. After one month of extended intensive phase, one specimen of sputum should be examined and the patients be put on the continuation phase, regardless of the smear result. In case of extension of the intensive phase based on positive smear results, the duration of the continuation phase will remain the same; hence the total treatment period will be extended by one month.

If the sputum is positive at month 5 or 6 the outcome will be registered as treatment failure. The patient must be re-registered as “treatment after failure” and be treated with a course of Category II regimen.

5.14.2 Retreatment smear-positive patients

One specimen of sputum of patients treated with Category II regimen should be examined at the end of month 3, 5 and 8. The sputum at eighth month can also be collected during the last two weeks of treatment.

Patients whose smear is positive at month 3 should continue the intensive phase for one more month. After one month of extended intensive phase, one specimen of sputum should be examined and the patients be put on the continuation phase, regardless of the smear result at month 4. In case of extension of the intensive phase based on positive smear
results, the duration of the continuation phase will remain the same; hence, the total treatment period will be extended by one month.

If the smear is still positive at month 5, patient should continue Category II treatment and meanwhile necessary steps should be taken for sputum culture and DST. If the patient remains smear positive after completion of the entire course of the treatment, the patient is no longer eligible for a new re-treatment regimen. In this case, the outcome will be recorded as “treatment failure” and the patient be considered as a “chronic case” and referred to a specialized hospital for further interventions.

5.14.3 Smear negative and extra-pulmonary patients

One specimen of sputum should be examined of smear-negative pulmonary TB at the end of month 2 to ensure that they remain negative. In case the smear is positive (a second smear should confirm the result), the patient should be put on Category II treatment and be re-registered as failure. If the sputum is negative the patients should continue the treatment and progress of the patient should be assessed clinically.

In case of extra-pulmonary TB, no smear examination is necessary and the patients should be assessed clinically.

Follow-up of patients after completion of treatment is not needed.

5.15 Actions in case of interruption of TB treatment

Table 3: Management of new smear-positive cases after interrupting treatment

<table>
<thead>
<tr>
<th>Length of treatment</th>
<th>Length of interruption</th>
<th>Result of smear</th>
<th>Record Rx Outcome</th>
<th>Re-register</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 1 month</td>
<td>Less than 1 month</td>
<td>Not required</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 1 and prolong it to compensate for missed doses</td>
</tr>
<tr>
<td>1-2 months</td>
<td>Positive</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 1 compensate the doses for 1 extra month</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 1 and prolong it to compensate for missed doses</td>
</tr>
<tr>
<td>Length of treatment</td>
<td>Length of interruption</td>
<td>Result of smear</td>
<td>Record Rx Outcome</td>
<td>Re-register</td>
<td>Treatment</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>------------</td>
<td>-----------</td>
</tr>
<tr>
<td>More than 2 months</td>
<td>Positive</td>
<td>Yes, record as defaulter</td>
<td>Yes, register as new</td>
<td>Restart CAT-I</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>Yes, record as defaulter</td>
<td>Go through flow chart</td>
<td>Depend on outcome of flow chart</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 1 and prolong it to compensate for missed doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 1 and prolong it to compensate for missed doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>Yes, record as defaulter</td>
<td>Yes, register as *RAD</td>
<td>Restart, now on CAT 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>Yes, record as defaulter</td>
<td>Go through flow chart</td>
<td>Depend on outcome of flow chart</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>No</td>
<td>No</td>
<td>Restart CAT 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*RAD: Return After Default*
Table 4: Management of re-treatment cases after interrupting treatment

<table>
<thead>
<tr>
<th>Length of treatment</th>
<th>Length of interruption</th>
<th>Result of smear</th>
<th>Record Rx Outcome</th>
<th>Re-register</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>More than 2 months</td>
<td>Less than 2 months</td>
<td>Positive</td>
<td>Yes: record as defaulter</td>
<td>Yes: return after default</td>
<td>Restart CAT 2*</td>
</tr>
<tr>
<td></td>
<td>1-2 months</td>
<td>Positive</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 2; 1 extra month</td>
</tr>
<tr>
<td></td>
<td>1-2 months</td>
<td>Negative</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 2, and prolong it to compensate for missed doses</td>
</tr>
<tr>
<td>More than 2 months</td>
<td>Positive</td>
<td>Yes: record as defaulter</td>
<td>Yes: return after default</td>
<td>Refer if patient becomes smear positive again**</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>Yes: record as defaulter</td>
<td>No</td>
<td>Refer if patient becomes smear positive again**</td>
<td></td>
</tr>
<tr>
<td>More than 2 months</td>
<td>Positive</td>
<td>No, (if treatment &lt;5 months)</td>
<td>No</td>
<td>Restart Cat 2*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>No</td>
<td>No</td>
<td>Continue CAT 2</td>
<td></td>
</tr>
</tbody>
</table>
5.16 Management of side effects or adverse reactions related to the use of anti-tuberculosis drugs

Most TB patients complete their treatment without any significant adverse effects of drugs. However, a few patients do experience adverse effects. Patients sometime discontinue the treatment due to major or even minor adverse effects. It is therefore important that patients be clinically monitored during treatment so that adverse effects can be detected promptly and managed properly. Routine laboratory monitoring is not necessary.

Health workers/ DOT providers can monitor side effects of drugs by teaching patients how to recognize symptoms of common side effects and to report if they develop such symptoms, and by asking about symptoms when the patients report to collect drugs.

Table 5: Symptom-based approach to side effects of anti-TB drugs and their management

<table>
<thead>
<tr>
<th>Side-effect</th>
<th>Drug(s) probably responsible</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor</td>
<td></td>
<td>Continue anti-TB drugs, check drug doses</td>
</tr>
<tr>
<td>Anorexia, nausea, abdominal pain</td>
<td>Pyrazinamide, rifampicin</td>
<td>Give drugs with after meals</td>
</tr>
<tr>
<td>Joint pain</td>
<td>Pyrazinamide</td>
<td>Give non steroidal anti-inflammatory drug (NSAID)</td>
</tr>
<tr>
<td>Burning sensation in the feet</td>
<td>Isoniazid</td>
<td>Give pyridoxine 100 mg daily</td>
</tr>
<tr>
<td>Orange/red urine</td>
<td>Rifampicin</td>
<td>Reassurance; the patient should be informed at the beginning of the treatment that it happens commonly and is normal</td>
</tr>
<tr>
<td>Itching with minor skin rash</td>
<td>All drugs</td>
<td>Exclude skin diseases</td>
</tr>
<tr>
<td>Major</td>
<td>Stop responsible drug(s)</td>
<td></td>
</tr>
<tr>
<td>Itching with skin rash</td>
<td>All drugs</td>
<td>Stop anti-TB drugs. Identify the offending drug (need expert opinion)</td>
</tr>
<tr>
<td>Deafness (no wax on auroscopy)</td>
<td>Streptomycin</td>
<td>Stop streptomycin and never use again</td>
</tr>
<tr>
<td>Dizziness (vertigo and nystagmus)</td>
<td>Streptomycin</td>
<td>Stop streptomycin and never use again</td>
</tr>
<tr>
<td>Jaundice (other causes excluded), hepatitis</td>
<td>Most anti-TB drugs (especially isoniazid, pyrazinamide and rifampicin)</td>
<td>Stop all anti-TB drugs until jaundice resolves (need expert opinion)</td>
</tr>
</tbody>
</table>
Vomiting and Confusion (suspect drug induced acute liver failure if jaundice present) | Most anti-TB drugs | Stop all anti-TB drugs until jaundice resolves. Urgent Liver function test and prothombin time test (need expert opinion)
---|---|---
Visual impairment (other causes excluded) | Ethambutol | Stop ethambutol and never use again
Shock syndrome, purpura, acute renal failure, acute hemolytic anemia | Rifampicin | Stop rifampicin and never use again

5.17 Treatment outcomes

At the end of the treatment course, one treatment outcome will be recorded for each TB patients. Table 6 shows the possible, mutually exclusive treatment outcomes.

**Table 6: Treatment outcome description**

<table>
<thead>
<tr>
<th>Treatment Outcomes</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Cure**           | A smear-positive patient will be declared cured if the following conditions are fulfilled:  
  * The entire course of 6(7) and 8(9) months of treatment has been completed;  
  AND  
  * The sputum smears are negative on at least two occasions: (i) At the end or during the last month of the treatment and (ii) on at least one previous follow up occasion, at least one month apart |
| **Treatment Completed** | If it is not possible to obtain sputum at the end of treatment from sputum positive patient, the patient has to be declared as “treatment completed” after completion of treatment (this should occur only in a minority of cases).  
  * A smear-negative or extra-pulmonary TB should be declared “treatment completed” after completing a full treatment course |
| **Treatment failure** | A patient who, while on treatment, remained smear-positive or became smear-positive again at 5 months or later after the start of treatment OR  
  * A patient who was initially smear-negative and was found smear-positive at the end of the second month of treatment |
| **Default** | A patient whose treatment was interrupted for two consecutive months or more |
| **Transfer out** | A patient who has been transferred to another recording and reporting unit and for whom the treatment outcome is not known (this should occur only in a minority of cases) |
| **Died** | Patient who died for any reason during the course of treatment. |
5.18 Referral and transfer of patients

A patient during treatment may require referral and/or transfer to another designated DOTS centre for continuation of treatment. In these cases, the medical officer of the referring/transferring centre should fill the Tuberculosis Referral/Transfer Form (TB 07) in triplicate. One copy should be sent to the referral/transfer center, one copy is given to the patient and one copy remains in the file of the treatment initiation center.

When treatment is continued in the receiving DOTS centre, the patient should be registered there as a “transfer in” case. The lower portion of the form (TB 07) should be returned to the centre from where the patient was referred.

If a patient was treated without being registered (e.g. in a hospital or by a private practitioner) and will continue treatment in the designated DOTS centre, this constitutes a referral and not a transfer. In this case, the receiving centre will register the patient as per treatment category (new, relapse, treatment after default, failure) and not as transfer in.

5.19 Treatment of tuberculosis in special situations

Patients with the following conditions can receive the usual short-course chemotherapy regimens provided there is no clinical evidence of chronic liver disease, hepatitis virus carriage, a history of acute hepatitis or excessive alcohol consumption. However, hepatotoxic reactions to anti-TB drugs may be more common among these patients and should therefore be anticipated.

Drug-induced hepatitis

Most anti-TB drugs can damage the liver. Isoniazid, pyrazinamide and rifampicin are most commonly responsible, ethambutol rarely. When a patient develops hepatitis during TB treatment, the hepatitis may be due to the anti-TB drugs but may also have another cause. It is important to rule out other possible causes before deciding that the hepatitis is drug induced. If the diagnosis of drug-induced hepatitis is made, the anti-TB drugs should be stopped. The drugs must be withheld until the jaundice or hepatic symptoms have resolved and liver function tests have returned to normal. If liver function tests cannot be done, then it is advisable to wait two weeks after the jaundice has disappeared before recommencing anti-TB treatment. In most cases the patient can restart the same anti-TB drugs without return of hepatitis. This can be done either gradually (one by one) or all at once (if the hepatitis was mild). However if the hepatitis produced severe jaundice, it is advisable to avoid pyrazinamide. A suggested regimen in such patient is 2SHE/10HE. A severely ill TB patient with drug-induced hepatitis may die without anti-TB drugs. In this case the patient should be treated with two of the least hepatotoxic drugs, streptomycin and ethambutol. After the hepatitis has resolved, usual TB treatment should be restarted. In case of extensive TB, ofloxacin can be considered in conjunction with streptomycin and ethambutol as an interim non-hepatotoxic regimen.

Acute viral hepatitis

TB treatment should be deferred until the acute hepatitis has resolved. When it is necessary to treat during acute hepatitis, the combination of streptomycin and ethambutol
for three months is the safest option. If the hepatitis has resolved, the patient can receive a continuation phase of six months isoniazid and rifampicin. If the hepatitis has not fully resolved, streptomycin and ethambutol should be continued for a total of 12 months.

**Chronic liver disease**

Patients with liver disease should not receive pyrazinamide. Isoniazid plus rifampicin plus one or two non-hepatotoxic drugs such as streptomycin and ethambutol can be used for total treatment duration of 8 months (2SHRE/6HR)

**Renal failure**

Isoniazid, rifampicin and pyrazinamide are either eliminated almost entirely by biliary excretion or metabolized into non-toxic compounds. These drugs can therefore be given in normal doses to patients with renal failure. Patients with severe renal failure should receive pyridoxine with isoniazid in order to prevent peripheral neuropathy.

Streptomycin and ethambutol are excreted by the kidney and can be given in reduced doses or intermittently where facilities for close monitoring of renal function are available. The safest regimen for patients with renal failure is 2HRZ/4HR.

**Pregnancy**

Most anti TB drugs are safe for use in pregnancy with the exception of streptomycin, which is ototoxic to the fetus.

**Breast-feeding women**

A woman with TB who is breast-feeding should receive a full course of anti-TB drugs. Regular and full course chemotherapy is the best way to prevent transmission of tubercle bacilli to her baby. The mother and baby should stay together and breast-feeding should be continued. Prophylactic treatment with isoniazid should be given for at least three months ahead of the time the mother is considered non-infectious. BCG vaccination of the newborn should be postponed until the end of the isoniazid prophylaxis.

**Women taking oral contraceptive pills.**

Rifampicin reduces the efficacy of estrogen thus increases the risk of pregnancy. A higher dose of estrogen (50 µ) can be used with rifampicin or another form of contraception may be used.

**Diabetes mellitus.**

During the course of anti-TB treatment a diabetes mellitus patient may require treatment with insulin.
6. TUBERCULOSIS IN CHILDREN

6.1. Background

Globally, of the 9.2 million new cases occurred in 2006, about 1 million (11%) were children (under 15 years of age). According to the Global WHO Report 2008, the National TB Control Program notified 3/100,000 population new smear-positive cases between the ages 0-14 years in 2006. Adults with smear-positive TB usually infect children but not all children develop the disease once infected. The likelihood of developing disease is high shortly after infection. Infants and children under 5 years are at particular risk of developing disease. Immunosuppressive illnesses including measles, malnutrition, whooping cough, and HIV infection facilitate progression of TB infection to disease. Children during coughing can produce sputum and therefore can infect others.

6.2. Clinical spectrum of childhood TB

Pulmonary TB is the disease of the lung parenchyma and hilar lymph glands. Children with pulmonary TB have chest X-ray changes suggestive of TB. Typically there is persistent opacity in the lung together with enlarged hilar lymph glands. Progression of pulmonary TB occurs by 1) extension of the primary focus with or without cavitary lesions; 2) the pathological processes caused by the enlarging lymph nodes, or 3) by spreading through lymphatic and/or hematogenous route. Most of the children with TB suffer from pulmonary TB. Extrapulmonary TB (EPTB) refers to TB of organs other than the lungs. EPTB is also quite common among children and the most common forms include TB lymphadenitis, TB meningitis, TB effusions (pleural, pericardial and peritoneal) and spinal TB.

6.3. Diagnosis of tuberculosis in children

Diagnosis of TB in children is difficult as most children can not produce sputum for microscopic examination and the Mantoux test (MT) is often negative in children with severe malnutrition and/or HIV/AIDS. Symptoms of TB are not typical in children. Infants (<1 year) with TB may present with acute severe pneumonia (fever, cough, breathing difficulty), and TB should be suspected when there is a poor response to antibiotics. In such situations, an identifiable source case is usually the mother.

### Key risk factors for TB in children

- Household contact with a known case of TB
- Age less than 5 years
- Severe malnutrition
- HIV infection

### Key features suggestive of TB in children

The presence of three or more of the following should strongly suggest a diagnosis of TB:

- Symptoms suggestive of TB
- Physical signs highly suggestive of TB
- A positive tuberculin skin test
- Chest X-ray suggestive of TB
6.3.1 Common symptoms of childhood TB are

- Chronic cough: an unremitting cough that is not improving with usual treatment has been present for more than 3 weeks;
- Fever: body temperature of \( >38^\circ C \) (\( >100^0 F \)) for 2 weeks, after common causes such as typhoid, malaria or pneumonia have been excluded;
- Severe malnutrition or not gaining weight or losing weight.

6.3.2 Physical signs highly suggestive of pulmonary and extra pulmonary TB (EPTB)

- No specific signs are suggestive for pulmonary TB
- A complete review of extra pulmonary tuberculosis in children is beyond the scope of monograph. For most forms of extra pulmonary tuberculosis, the clinical presentation is similar in children to that in adults. However the following signs are highly suggestive of extra pulmonary TB:
  - Painless enlarged cervical lymphadenopathy with or without sinus formation;
  - Gibbus (an angulation of the vertebral column resulting from vertebral TB).

6.3.3 Physical signs requiring investigation to exclude extra pulmonary TB (EPTB)

- Meningitis not responding to antibiotic treatment, with a sub-acute onset or raised intracranial pressure;
- Pleural effusion;
- Pericardial effusion;
- Distended abdomen with ascites;
- Non-painful enlarged lymph nodes without fistula formation;
- Non-painful enlarged joint;
- Signs of tuberculin hypersensitivity (e.g. erythema nodosum, phlyctenular conjunctivitis).

Table 7: Common forms of extra-pulmonary tuberculosis (EPTB) in children

<table>
<thead>
<tr>
<th>Site</th>
<th>Practical approach to diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral lymph nodes (especially cervical)</td>
<td>Lymph node biopsy or fine needle aspiration cytology (FNAC)</td>
</tr>
<tr>
<td>Miliary TB (disseminated TB)</td>
<td>Chest X-ray</td>
</tr>
<tr>
<td>CNS TB</td>
<td></td>
</tr>
<tr>
<td>• TB meningitis</td>
<td>CSF study (very high protein, increased white blood cell count predominantly lymphocytes)</td>
</tr>
<tr>
<td>• Tuberculoma of the Brain</td>
<td>CT / MRI</td>
</tr>
<tr>
<td>Pleural effusion (older children)</td>
<td>Chest X-ray, pleural fluid study for cells, protein, glucose, AFB (ZN staining and culture)</td>
</tr>
<tr>
<td>Abdominal TB (e.g. peritoneal)</td>
<td>Ascitic fluid study, abdominal ultrasound</td>
</tr>
<tr>
<td>TB Arthritis/Bone TB</td>
<td>X-ray, joint fluid study</td>
</tr>
<tr>
<td>Pericardial TB</td>
<td>CXR ; Echocardiography</td>
</tr>
</tbody>
</table>
6.3.4 General approach to diagnosis of TB in Children

**Symptoms with or without risk factors**

**Physical examination**

**Pulmonary Disease**
- Child Able to produce sputum
  - CXR – ve and MT Positive
  - Request sputum smear test
    - Sputum smear + ve
      - CXR + ve and MT Positive
    - Sputum smear –ve
      - Treat for TB

- Child not able to produce sputum
  - Request CXR and MT
    - CXR – ve and MT Positive
    - Refer for expert opinion
    - CXR – ve and MT Negative
      - Follow up

**Extra-pulmonary Disease**
- Cervical Glands
  - Biopsy or FNAC + ve
- Other EPTB
  - MT
  - Pleural aspirate
  - Ascitic fluid aspirate
  - Lumber puncture
  - Joint aspirate
  - Echo
  - CT Scan/X-ray/USG (As per decision of the specialist)
  - Manage as per expert opinion
6.3.5 Tuberculin skin test- Mantoux Method

The Mantoux test is used as an adjunct in diagnosing TB in children with signs and symptoms of TB. The test is performed by injecting 0.1 ml reagent containing 5 tuberculin units of tuberculin purified protein derivative or 2 TU of tuberculin PPD RT23 into the anterior aspect of the forearm using a disposable tuberculin syringe with 10 mm long, 26-gauge needle. During injection, the skin is slightly stretched in the direction of the needle. The bevel of the needle should face up towards the injector; the needle is introduced into the superficial layer of the skin almost parallel to it. The volume is injected slowly to produce a pale wheal.

A health worker who has experience in administration and reading of MT reads the test after 72 hours. The reading is limited to measurement of the induration at the test site; the area of erythema or redness should not be measured. The site is gently palpated with the tip of the index finger, keeping the forearm of the child slightly flexed and if induration is present, its margins are determined and marked with a ballpoint pen. The widest transverse diameter (relative to the long axis of the forearm) of the induration is measured in millimeters using a 10 cm transparent ruler. If there is no palpable induration, "0" is recorded.

A Mantoux test should be regarded as positive in the following circumstances:
- In severely malnourished children (marasmus or kwashiorkor) or with HIV infection, ≥5 mm of induration. Marasmus is defined as weight-for-age less than -3 standard deviations or <60% of NCHS median; kwashiorkor is weight-for-age more than -3 standard deviations or >60% of median plus pedal edema.
- In all other children (whether they have received BCG vaccine or not), a ≥10 mm of induration.

6.3.6 Radiological examination

In childhood pulmonary tuberculosis, the radiographic hallmark is the relatively large size of parahilar lymph nodes compared with the less significant size of the parenchymal focus. Lymphadenopathy is invariably present with childhood TB but may not be apparent on chest X-ray when other pulmonary findings are present. In most cases of pulmonary TB in children, the mild parenchymal infiltrate and lymphadenopathy resolve spontaneously, the chest radiograph remains normal, and the child is asymptomatic. In some children, the hilar and mediastinal lymph nodes continue to enlarge and are readily visible on chest radiograph. Occasionally, children have a picture of lobar pneumonia without impressive lymphadenopathy. If the infection is progressively destructive, liquefaction of the lung parenchyma leads to formation of a thin-walled primary tuberculous cavity. Other children and adolescents can develop the more typical adult type of reactivation TB.

6.3.7 Bacteriological confirmation

Bacteriological confirmation of TB should be done whenever possible. Sputum examination should be done for all children from 8 years or more and even in children aged less than that if they can produce sputum. Facilities for culture of *Mycobacterium tuberculosis* are available in the National Institute of Chest Diseases and Hospital (NIDCH) at Mohakhali, Dhaka, Chest Disease Hospital in Rajshahi, Chest Disease Clinic Shymoli, Dhaka and three clinics run by government accredited NGO the Damien Foundation in Netrokona, Mymensingh, Tangail.
6.4 Treatment of tuberculosis in children

Children usually have paucibacillary pulmonary disease with low number of bacteria, as cavitating disease is rare (less than 6% of cases). In contrast, extrapulmonary TB is more common than in adults. Severe and disseminated TB (e.g. TB meningitis and miliary TB) occur especially in children less than 3 years old. Treatment outcomes in children are generally good and the risk of adverse effects is low with use of the recommended treatment regimens.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose and range (mg/kg body weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td>5 (4-6)</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>10 (8-12)</td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td>25 (20-30)</td>
</tr>
<tr>
<td>Ethambutol¹</td>
<td>20 (15-25)</td>
</tr>
<tr>
<td>Streptomycin²</td>
<td>15 (12-18)</td>
</tr>
</tbody>
</table>

¹ Ethambutol is now considered to be safe in children at a dose of 20 mg/kg (range 15-25 mg/kg) daily.
² Streptomycin should be avoided when possible in children because the injections are painful and irreversible auditory damage may occur. It is mainly reserved for the first 2 months of treatment of TB meningitis.

6.4.1 Recommended treatment regimens for children

The recommended treatment regimens for children for each TB diagnostic category are generally the same as for adults. New PTB cases as well as extrapulmonary TB cases fall in category I. Most children with TB have uncomplicated (smear-negative) pulmonary TB or extra pulmonary TB, and therefore fall under diagnostic category I. Children with TB meningitis and miliary TB deserve special mention.

<table>
<thead>
<tr>
<th>TB diagnostic category</th>
<th>TB cases</th>
<th>Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>New smear-positive pulmonary TB</td>
<td>2(HRZ) E</td>
</tr>
<tr>
<td></td>
<td>New smear-negative pulmonary TB</td>
<td>4 (HR)</td>
</tr>
<tr>
<td></td>
<td>Different forms of extrapulmonary TB (other than TB meningitis)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Severe concomitant HIV disease</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>TB meningitis</td>
<td>2RHZS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4RH</td>
</tr>
<tr>
<td>II</td>
<td>Previously treated smear-positive pulmonary TB (relapse, treatment after interruption, treatment failure)</td>
<td>2HRZES/1HRZE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5HRE</td>
</tr>
</tbody>
</table>
* Chronic and MDR-TB    | Specially designed standardized regimens                                 |

E, ethambutol; H, isoniazid; R, rifampicin; S, streptomycin; Z, pyrazinamide
Dispersible, fixed-dose combination (FDC) tablets are now available with the National TB Control Programme. During the initial phase of 2 months, treatment is with 3FDC tablets each containing rifampicin 60 mg, isoniazid 30 mg, and pyrazinamide 150 mg. In addition ethambutol should be given according to body weight. During the continuation phase of four months, 2FDC tablets each containing rifampicin 60 mg and isoniazid 30 mg are given. This is written as 2(HRZ) E/4HR. The table below shows the drugs and age-specific dosage for the initial phase and continuation phase of treatment.

Table 10: Drugs and age-specific dosage for the initial and continuation phase of treatment for children

<table>
<thead>
<tr>
<th>Body weight in kg</th>
<th>Initial Phase</th>
<th>Continuation phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of 3FDC(R/H/Z: 60/30/150mg) + E(400 mg) Daily during first 2 months</td>
<td>No. of 2FDC(RH: 60/30mg) Daily during next 4 months</td>
</tr>
<tr>
<td>2-3</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>4-7</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>8-14</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>15-19</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>20-29</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

6.4.2 Use of corticosteroids

Corticosteroids may be used for the management of complicated forms of TB, e.g. TB meningitis, airway obstruction by enlarged TB lymph glands, and pericardial TB. In cases of TB meningitis, steroids have been shown to improve survival and decrease morbidity and are therefore recommended in all cases of TB meningitis. Prednisone, 2 mg/kg daily, in very critically ill patients, with a maximum dose of 60 mg/day for 4 weeks. The dose should be gradually tapered over 1-2 weeks before stopping.

6.5. Miliary TB in children

There are no specific clinical features. Features commonly associated with miliary TB include fever, wasting, cough, lymphadenopathy and splenomegaly. The MT may be false negative and the diagnosis is based on typical chest x-ray findings of miliary mottlings.

6.6 Tuberculous meningitis in children

Tuberculous meningitis (TBM) is a disease with insidious onset and is fatal if left untreated. The course of illness is divided into three stages.

1. Stage of invasion or prodromal stage: Symptoms are non-specific and include apathy, irritability, headache, vomiting and mild fever.

2. Stage of meningitis: There are manifestations of meningism i.e. headache, vomiting, fever, convulsions, bulged anterior fontanellae in infants, altered mental status. Neck rigidity appears, Kernig's sign may be positive with a plantar extensor response. Ocular paralysis, strabismus and nystagmus may occur. Papilledema may be present.
3. Stage of coma or terminal stage: Case fatality is high in this stage. The incidence of hydrocephalus, blindness, deafness and mental retardation is high among survivors. At this stage, the child is comatose, may have convulsions, head retraction or decerebrate rigidity.

Classically the cerebrospinal fluid shows lymphocytosis with high protein and low sugar levels. It forms a clot like a cobweb if left in a test tube placed in a refrigerator.

Children with tuberculous meningitis should be hospitalized and given streptomycin, 15 mg/kg per day, during the initial phase in addition to HRZ. Pyrazinamide is concentrated in the CSF and is, therefore, particularly useful in tuberculous meningitis. In order to reduce inflammation and prevent blockage of CSF flow, corticosteroids are given as mentioned above.

6.7 Chemoprophylaxis for children

Children aged less than 1 year, whose house hold contacts are under treatment for TB, should be given chemoprophylaxis with isoniazid 5 mg/kg per day for 6 months irrespective of BCG status and the child is free of active TB. Follow-up should be carried out at least every 2 months until completion of treatment. An infant born to a mother with infectious pulmonary TB can be safely breastfed if given isoniazid prophylaxis. If a child receiving isoniazid develops symptoms, assessment for TB should be done. If the child has not been BCG vaccinated, BCG should be given after completion of isoniazid treatment.

6.8 BCG vaccination

BCG vaccine is recommended as soon as possible after birth. The vaccine is known to prevent the more severe types of TB such as TB meningitis and miliary TB. However, the efficacy of the vaccine in general ranges from 0% to 80%. The reasons for this variability are: different types of BCG used in different countries, differences in the strains of M tuberculosis prevailing in different regions, different levels of exposure, etc. Revaccination offers no added protection, and is therefore not recommended.

A small number of children (1-2%) develop complications following BCG vaccination. These include local abscesses, secondary bacterial infections, suppurative adenitis, and local keloid formation. Most reactions resolve over a few months. Children who develop disseminated BCG disease should be treated for TB and investigated for immunodeficiencies.

The assessment should include inquiry about symptoms, treatment adherence, adverse events, and weight measurement. Dosage of anti-TB medicines should be adjusted to account for any weight gain. Follow-up chest X-rays are not routinely required as many children will have a slow radiological improvement.

BCG acceleration is not recommended
7. RECORDING AND REPORTING

A standardized recording and reporting system is an important component of DOTS. It allows for assessment of case detection and treatment outcome against the targets set. It also allows for maintaining surveillance and monitoring with a regular two-way communication between central and peripheral levels.

The programmatic progress and achievements of NTP should be assessed at the different implementation levels: upazila, district, city and central levels.

The NTP recording and reporting system consists of standardized cards, registers and reports. The description of forms and cards are given below (All samples of forms and cards are also available in Annex 2).

7.1 Tuberculosis Treatment Card (TB 01)

The medical officer or paramedic fills the Tuberculosis treatment card as soon as a patient is diagnosed with TB. The card is kept at the health facility where the patient is treated. In the front page during Intensive phase for the treatment of New cases the dose of 4FDC tablet and in case of Retreatment the dose of streptomycin in addition to 4FDC should be written in the box. If a patient is treated with single or multiple loose drugs the daily dosage should be filled in the boxes for H, R, Z, and E. On the back page similarly during Continuation phase the dose of 2FDC tablet for New cases should be filled in the box. In addition the dose of Ethambutal should be added for Retreatment cases. If the patient is treated with single or multiple loose drugs, the doses should be filled in the appropriate boxes. There is a special box for child TB. The doses of child TB should be filled in the box accordingly.

7.2 Tuberculosis Identity Card (TB 02)

The medical officer or paramedic fills this card as soon as the diagnosis of tuberculosis is made and the patient keeps the card. The most important parts of this card are the date on which treatment was started, and categorization of the patient. The patient should be instructed to bring this card each time (s)he attends for anti-TB treatment, but (s)he should also bring and show it if (s)he attends for any complaint at a health facility, as the complaint might be caused by the anti-TB drugs.

7.3 Tuberculosis Treatment Register (TB 03)

This register is kept at the TB treatment facility. The Tuberculosis Register contains all the important general information of the patient, classification of the disease, type of patient, date of start of treatment, smear microscopy results and outcome of the treatment. The date of registration is the date the patient is registered in the Tuberculosis Register and may be different from the date the patient was diagnosed in the laboratory or started treatment. At the end of each quarter a line should be drawn beneath the last patient registered during that quarter to highlight the end of the quarterly cohort. This will facilitate preparation of the quarterly reports and cohort analysis of treatment outcome. At the end of the quarter, a tally can be made per sex (males and female patients), disease classification, type of patient or treatment outcome. A new page should be used for starting a new quarter.
From this register the quarterly reports on case-detection and treatment outcome will be compiled. It is the responsibility of the staff that maintains the register to keep it up-to-date.

7.4 Tuberculosis Laboratory Register (TB 04)

The tuberculosis laboratory register is kept at all laboratories performing sputum examination for AFB. The microscopist or technologist who examines the smears enters all information into the register. The register gives information on the number of suspects examined, the number of smear-positive cases detected and the number and results of smear examination for follow-up of treatment. The TB registration number is the serial number and should be started with 1 at the beginning of each calendar year. At the end of each quarter a line should be drawn beneath the last patient entered in the register. After each quarter, the number of suspects and number of total smears of suspects examined, number of smear-positive patients, number of follow-up examinations and number of positive follow-up examinations should be entered. Source of referral can also be tallied. The next quarter can start on a new page but the serial number will continue throughout the year.

7.5 Request form for sputum examination (TB 05)

The medical officer or paramedic who requests the smear examinations should fill in this form. If the smears are examined at the facility where the patient attends, the form should be brought to the laboratory with the first “on-the-spot” specimen. The patient should be given a sputum cup for the early morning specimen and a third cup for the second “on-the-spot” specimen when (s)he attends the next morning. If smears are examined at another facility, the three smears with the filled-in request form should be brought to the examining laboratory. It is essential to mention whether the sputum is sent for diagnosis or follow-up. A detailed address (including mobile phone number) of the patient should be recorded if sputum is sent for diagnosis. This is important to trace the patient if sputum is found positive and the patient does not return to the health facility.

7.6 Tuberculosis culture/DST request form (TB 06)

Tuberculosis culture and drug-susceptibility testing will be carried out at the NIDCH, Laboratory of National TB Control Project Shyamoli, Dhaka and Regional Reference Lab at Rajshahi and Lab. of Damien Foundation hospital in Netrakona for studies on surveillance of drug resistance and for selected patients as instructed by the NTP management (5.20).

7.7 Tuberculosis referral/transfer form (TB 07)

This form is used for referring or transferring patients from one health facility to another. It should be filled in triplicate: one copy goes to the receiving center, one is given to the patient and one remains in the file. The receiving facility should fill the bottom part of the form and return it to the sending institution as soon as the patient reports.

7.8 Drug request form (TB 08)

This form should be filled half yearly with a copy to District authority. For the drug calculation requirement of each item is calculated by multiplying the number of cases in the last quarter (category wise), the number of treatment doses and average units per dose by
which working stock or running requirement will be obtained. This figure is multiplied by 3 to obtain stock of two quarter and 50% buffer stock (i.e., buffer stock of one quarter). By subtracting the in hand stock at the time of the indent from the above multiplication result, drug requirement for each item of drug for the bi-annum will be obtained.

7.9 Absentee tracing form (TB 09)

This form should be used for retrieval of patients who do not turn up for their scheduled drug intake.

7.10 Quarterly report on case finding Tuberculosis (TB 10)

How to make the report?
- Identify all patients registered in the Tuberculosis Register during the quarter under report.
- Looking at the columns “Category” and “Pre-treatment smear examination”, count the number of new male smear-positive cases, putting a mark with a pencil after a patient has been counted.
- Continue in the same way with the new female smear-positive cases.
- All new smear-positive cases have now been identified and they should be entered in the block-I (column-1),
- Divide the new smear-positive male and female patients according to the age groups and record the number in block-2. Verify that the number of males and the number of females for all age groups together should be the same as the numbers reported in block 1.
- Count (and mark) the smear-positive relapses, then new smear-negative cases and then new extra-pulmonary cases and other (previously treated & declared as treat. completed) in the same way.
- Enter these sums in the columns 2 to 5 of block 1. Add the totals of column 1-5 and enter in column 6.
- Verify that all patients registered during the quarter concerned have been included in the report.
- The reporting form should be filled in triplicate. One copy should be sent to the District Medical Officer, one to the NTP HQ in Dhaka and one should be kept in the records. The report should be sent promptly after the respective quarter is finished.

7.11 Quarterly Report on Treatment Results (TB 11)

This report is for cohort analysis of the treatment results. The different types of patients are evaluated separately. The evaluation is made quarterly of the cohort that started the treatment 12-15 months earlier. The information should be collected from the updated Tuberculosis Register.

Different categories of the treatment outcome
- For new smear-positive patients and retreatment patients
  - Cured (2 negative smears of which one at the end of treatment)
  - Treatment completed (no smear result at the end of treatment)
  - Died (of any cause during treatment)
For smear-positive patients
- Failure (smear positive at 5 months or more after start of treatment)
- Defaulted (absent for two or more consecutive months)
- Transferred out (transferred to a facility outside the administrative recording/reporting area)

For smear-negative patients
- Treatment completed (finished the 6 months of treatment)
- Died (of any cause during treatment)
- Failure (smear positive at 2 months after start of treatment)
- Defaulted (absent for two or more consecutive months)
- Transferred out (transferred to a facility outside the administrative recording/reporting area)

The report should be prepared in the same way as the case finding report.

7.12 Quarterly Report on Sputum conversion at 2/3 Months of Smear-positive Pulmonary TB Cases (TB 12)

This report provides information about the smear result at the end of the first two months (new smear-positive patients) or three months (retreatment patients) of treatment. In the best circumstances up to 10-15% of patients will remain positive at the end of the intensive phase. If the percentage is lower, this may indicate that scanty or low-positive smears are missed and thus provide an idea about the quality of microscopy. The report should be prepared in the same way as the case finding report.


This report provides information about the smear result during diagnosis and follow up examination of a patient. It will also provide information regarding total no of suspects examined & total no smear positive cases detected.

7.14 Laboratory Logistic Request Form

This form should be filled in every quarter by the district staff responsible for supplies, with copy to the district authorities. The amounts required depend on the numbers of smear-positive patients diagnosed during the previous quarter and for some supplies on the number of diagnostic centres. This form is annexed in 5.

7.15 Times of Preparation of Reports

The following table helps to memorize when to send the reports to the district/national authorities. The reports should be sent within four weeks after the quarter is finished. A cohort is a group of patients diagnosed and registered for treatment during a quarter. A year is divided into 4(four) quarter so each quarter contain3 (three) months.

<table>
<thead>
<tr>
<th>Reporting on</th>
<th>Case finding (form TB 10)</th>
<th>Smear conversion (form TB 12)</th>
<th>Treatment result (form TB 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1.04</td>
<td>4th Quarter03</td>
<td>3rd Quarter03</td>
<td>4th Quarter02</td>
</tr>
<tr>
<td>1.4.04</td>
<td>1st Quarter 04</td>
<td>4th Quarter03</td>
<td>1st Quarter 03</td>
</tr>
<tr>
<td>1.7.04</td>
<td>2nd Quarter 04</td>
<td>1st Quarter 04</td>
<td>2nd Quarter 03</td>
</tr>
<tr>
<td>1.7.04</td>
<td>3rd Quarter04</td>
<td>2nd Quarter 04</td>
<td>3rd Quarter03</td>
</tr>
</tbody>
</table>
8 SUPERVISION, MONITORING AND EVALUATION

8.1 SUPERVISION

Supervision is the key element of TB control and is considered a cornerstone for sustainability of different NTP activities. It is the process of helping people to improve their own performance in order to meet objectives. Supervision is the part of monitoring that looks at the job performance of the people in the programme.

All health workers need help to solve problems and overcomes difficulties. They need feedback on their performance and encouragement in their work.

Supervision should encourage, motivate, train, support, monitor, guide and boost staff morale. It is a set of activities to improve staff competence, effectiveness and efficiency of work through observation, discussion, technical support and reviewing records. The focus of supervisory visits is on education through on-the-job training, coordination, motivation, facilitation and guidance in implementation as per NTP guidelines with the overall objective to achieve national targets and goals.

Supervisory visits are planned with the following aims:
- To ensure effective implementation.
- To provide technical guidance and administrative support.
- To validate reported data.
- To effect corrective measures wherever required.
- To ensure patient and staff satisfaction
- To strengthen the relationship between the central, intermediate and peripheral levels and the implementing staff

8.1.1 NTP supervision policy

8.1.2 Process of supervision

Supervisory visits must be planed carefully. A schedule for supervisory visit should be prepared in advance. Before each visit, it is important to review the findings of the last
supervisory visit, any notes of actions taken since the last visit, and any additional information about the health facility.

8.1.3 Tools for supervision

**Supervisory checklist**

Supervisory checklists are to be used to identify the administrative and technical problems systematically (Annex 3). They should be systematically filled in, calculating all indicators and answering all questions, together with the health worker. The checklist should be completed upon the end of the supervisory visit. The check list provides a guide but a supervisory visit may never be limited to completing the check list.

8.1.4 Points to be focused during supervision

**General**

- Availability of TB operational manual and other manuals including laboratory manual; also availability of health promotion materials for TB;
- Human resources: staff status (post sanctioned and vacant), availability of job description; training status of staff; knowledge, skills and attitude of relevant staff, job satisfaction.

**Identification of suspects and laboratory diagnosis**

- Trends in suspects: number of TB suspects per month; suspect notification rate (TB suspects detected in a defined period in a defined geographic area / total population of that area x 100,000) – inquire about any unexpected situation and provide feedback; quality of suspects; number of sputums examined per suspect (when there are several suspects for whom less than three sputum have been examined, may point out to poor counselling about the diagnostic procedure or wrong patients suspected for TB); source of referral of suspects;
- Triangulation: check that all patients diagnosed in the TB Laboratory Register have started treatment (treatment card available) and are registered in the TB register. Check for any inconsistency between the three forms.
- Check that smear-negative TB suspects are referred to a qualified physician for further investigations according to TB diagnostic algorithm.
- Calculate sputum positivity rate among TB suspects and during follow up. This amount should be around 10% for both suspects and follow up smears. Inquire in case of any very low or very high sputum positivity rate.
- Check the quality of smear (size, thickness, evenness, staining)
- Check maintenance of microscope and other equipments and logistics
- Check adequate supply of laboratory consumables
- Check Infection control measures taken (patients waiting area, sputum collected outside, availability and use of mask, etc.)
Verifying TB records

- Trends in case notification: number of TB cases per month (smear-positive cases, retreatment cases, all cases); notification rate (cases detected in a defined period in a defined geographic area / total population of that area x 100 000) – inquire about any unexpected situation and provide feedback;

- Sputum conversion rate (Total number new smear-positive cases becoming smear-negative after two months of treatment / total new smear-positive cases registered during the same quarter x 100% or total number of retreatment smear-positive cases becoming smear-negative after three months of treatment / total retreatment smear-positive cases registered during the same quarter x 100%). This rate is expected to be around 85-90%. Inquire in case of any low conversion or very high conversion and provide feedback.

- Treatment success rate: Total number of new smear-positive cases who were declared “cured” or “Treatment Completed” / total number of new smear-positive cases registered in the same period x 100%. This rate can be calculated in the same way for retreatment cases, smear-negative cases and extra-pulmonary cases. Inquire about any unexpected situation and provide feedback. The treatment completion rate for smear-positive cases should not exceed 5%.

- Unsuccessful outcomes (default rate, failure rate and transferred-out rate): Total number of new smear-positive cases who “defaulted”, “failed” or were “transferred out” / total number of new smear-positive cases registered in the same period x 100%. These rates can be calculated in the same way for retreatment cases, smear-negative cases and extra-pulmonary cases. Inquire about any unexpected situation and provide feedback.

Health education and counselling

- Check availability and use of health education materials.

- Check counseling procedures.

- Interview a selected number of patients to relate your findings with the information available on the patient cards, check knowledge about the diseases, duration of treatment and consequences of interruption of treatment.

8.1.5 Supervision Report

Feedback is one of the most important parts of the supervision. It is encouraging to fill the checklist on the spot together with the related health personnel that will facilitate to strengthen a good relationship. Supervision reports should be submitted to relevant authorities and feedback must be provided to relevant field authorities.

8.2 Monitoring

Monitoring means to watch, keep track, or check usually for a special purpose. In our case it relates to maintaining and improving the health care for TB patient and suspects so that it meets our aspirations, to take appropriate action to improve performance. It is an ongoing process carried out by the programme implementers. Monitoring is the activity that
ensures that measurable information of a programme is implemented, recorded and reported.

8.2.1 Methods of Monitoring

- Routine reporting
  - the core of a monitoring system
  - focus on data management, supply, finance, training, quality assurance, and drug use
- Supervisory visits
  - reinforce routine reporting requirements
  - provide on-the-spot training, informal and direct monitoring
- Sentinel reporting
  - supplements routine reporting
  - most useful when a system is undergoing rapid or substantial change; can detect unexpected or unintended outcomes
- Special studies
  - when additional information and use of experts to design and conduct the study are required.

Both monitoring and supervision are ongoing processes. There should be a plan for regular supervision and monitoring at all levels.

8.3 EVALUATION

Evaluation is the result of the programme that is measurable. It indicates whether the programme has achieved its targets and takes necessary steps for developing strategies and interventions for further improvement as per requirement of the programme.

The NTP advocates for continuous monitoring of the programme internally on periodic basis. The external joint evaluation is being conducted by both programme and external national and international experts at an interval of two to three years.
9. SUPPLY OF DRUGS, LABORATORY CONSUMABLES AND DOCUMENTATION MATERIALS

A regular, uninterrupted supply of quality drugs, laboratory consumables and documentation materials to all facilities where patients are diagnosed and treated should be ensured. Diagnosis of through smear microscopy and treatment of all registered TB patients are provided free of charge, including in nongovernmental and private settings formally linked to NTP. The central level of NTP is responsible for planning, procurement and supply of anti-TB drugs, laboratory consumables and documentation materials to its implementing partners.

9.1 Requirement of drugs

Quantification of anti-TB drugs is usually done annually by the central level of NTP with the technical assistance of WHO and the Global Drug Facility (GDF). This estimation of amounts of drugs required is based on the number of TB cases (category wise) treated during the previous year, annually adjusted; treatment regimen adopted, buffer stock (including amount of drugs required during lead time to supply) and stock-in-hand at the time of the drug order.

Quantification of anti-TB drugs at the upazila, CDC or city level is usually done quarterly according to the number of patients diagnosed during the previous quarter. Local health authority in collaboration with NGOs will calculate the quantity of drugs required and fill in the requisition form for drugs (TB 08) at the end of every quarter. The form will be signed by the Upazila Health and Family Planning Officer (UH&FPO) or unit chief, countersigned by the Civil Surgeon (or supervisor for the unit) and forwarded to the central level preferably within the first week of the following month. The relevant NGOs will collect the drugs from central level and will deliver to respective indenting authority. Alternatively, the NTP may arrange for supply of the drugs to the indenting authority.

The NGOs will collect the required drugs from the UHC through indent to the UH&FPO on quarterly basis and will report consumption and balance of drugs and other delivered logistics / laboratory consumables to the respective UH&FPO.

The information about drug consumption and stock at upazila level will be communicated to the central level quarterly together with case finding and treatment result reports. It is the responsibility of the UH&FPO (or unit chief) to ensure that this information is sent in time to avoid delays of supplies. The buffer stock of drugs and laboratory consumables for peripheral stores will be for one quarter.

9.2 Requirement of Laboratory Consumables

All health facilities require an adequate supply of sputum containers to collect and transport sputum specimens to microscopy centers. TB laboratories need a good quality binocular microscope, regular supply of slides and reagents. The “Laboratory Request Form” (Annex A) gives information on how to calculate the required quantities of the ingredients for the stains and other supplies. Further details are given in the “Laboratory Manual on Smear Microscopy for Tuberculosis and its Quality Control in the NTP of Bangladesh”.

46
9.3 Requirement of Documentation materials

Each registration unit needs a TB Register (one register will usually be sufficient for one year), TB treatment cards and patient identity cards based on the estimated number of patients. Sputum request forms should be available in the TB diagnostic facilities. One sputum request form is sufficient for requesting diagnostic examination of three sputum specimens for a TB suspect and one for each follow-up examination during treatment. Each laboratory needs one or more TB laboratory registers per year depending on the number of suspects and follow-up cases examined. On an annual basis, all registration units (UHC, CDC, urban clinic, medical college hospital, etc.) need 25 copies of the quarterly report forms on case finding, smear conversion and treatment outcome. All districts need 15 copies of the “Requisition Form for Drugs” and the” Laboratory Request Form”. NTP will ensure procurement of the documentation materials and its supply as per indent.

9.4 Inspection and Storage of Drugs and Supplies

Upon receipt, all drugs and supplies should be inspected by a ‘Survey Committee’ constituted for the store. The committee will tally the supplies with the ‘Invoice’ and will report for discrepancies or damages, if any.

Drugs and supplies should be stored in optimum conditions in a secured room. The drugs and laboratory reagents should be monitored regularly for expiry date. The drugs with shorter expiry dates should be placed in front and those with longer expiry dates behind (FEFO or first expiry-first out). A stock ledger must be maintained and updated whenever drugs and other materials are received or dispensed. In addition, a stock card (bin card) should be maintained for each drug. The bin card must be updated whenever drugs are received or dispensed, so that it always tallies the actual balance in stock as well as with the stock ledger.

The officer in charge of the store will ensure inspection of supplies, its optimum storage and proper recording as detailed in the “Standard Operating Procedures for Managing Drugs and Supplies”.

9.5 Issuance of Drugs and Supplies

Considering the number of indenting centers and consequent workload, NTP will workout a ‘schedule of distribution’ mentioning the weeks, week days and districts for which the supplies will be issued. ‘The distribution schedule’, approved and signed by Director or his/her nominated person, should be available to the all concerned well ahead. The week of a quarter / bi-annum for a district should be similar for each quarter / bi-annum. The completed TB 08 form should be available to NTP well ahead of the schedule for distribution.

The NTP Medical Officer designated to supervise the Central Store should be responsible for following the distribution schedule as detailed in the “Standard Operating Procedures for Managing Drugs and Supplies”.

9.6 Monitoring and Supervision of Stores

Monitoring and supervision of drugs/supplies management must be done at all levels. Reports of case finding and drug stock status from the upazila received through indent form as well as quarterly stock status from the Central Store should be the raw material for
monitoring. Drug/supply management (especially GDF drugs) should be included in the agenda of monitoring meetings at all levels.

Supervisory visits including drug/supply management should be done by using a checklist as revised and included in the general supervisory checklist.

Reports of the supervisory visits should be analyzed for monitoring and feedback.
10. **DRUG-RESISTANT TUBERCULOSIS**

10.1 Definition and causes of multidrug-resistant tuberculosis

Multidrug-resistant tuberculosis (MDR-TB) is defined as TB resistant to at least isoniazid and rifampicin, the two most potent anti-TB drugs.

Although its causes are microbial, clinical and programmatic, MDR-TB is essentially a man-made phenomenon. From a microbiological perspective, resistance is caused by a genetic mutation that makes a drug ineffective. An inadequate or poorly administered treatment regimen allows drug-resistant mutants to become the dominant strain in a patient infected with TB. The table below summarizes the common causes of inadequate treatment. The most frequent mistakes include wrong classification of patients (Category 1 given to unrecognized retreatment cases) and the addition of a single drug to failing regimen.

<table>
<thead>
<tr>
<th>Health-care providers: inadequate regimens</th>
<th>Drugs: inadequate supply/quality</th>
<th>Patients: inadequate drug intake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noncompliance with guidelines</td>
<td>Poor quality</td>
<td>Poor adherence</td>
</tr>
<tr>
<td>Poor training</td>
<td>Unavailability of certain drugs (stock-outs or delivery disruptions)</td>
<td>Lack of information</td>
</tr>
<tr>
<td>No monitoring of treatment</td>
<td>Poor storage conditions</td>
<td>Lack of money</td>
</tr>
<tr>
<td>Poorly organized or funded TB control programmes</td>
<td>Wrong dose or combination</td>
<td>Lack of transportation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adverse effects</td>
</tr>
</tbody>
</table>

Treatment of MDR-TB with Category 1 or 2 may create even more resistance to the drugs used. This has been termed the “amplifier effect” of the short-course chemotherapy. Ongoing transmission of established MDR-TB strains in a population may also contribute to new drug-resistant cases.

10.2 Addressing the sources of drug-resistant TB

Any ongoing production of MDR-TB should be addressed urgently before embarking on any programme designed for MDR-TB control. Well-administered first-line treatment for susceptible cases is the best way to prevent acquisition of resistance. Timely identification of MDR-TB and adequate treatment regimens with second-line drugs administered early in
the course of the disease are essential to stop primary transmission. Integration of DOTS with treatment of MDR-TB works synergistically to eliminate all the potential sources of TB transmission.

10.3 Types of drug resistance

Depending on the number of resistant drugs, we distinguish the following categories of resistance:

- Monoresistance: resistance to one type of drugs (e.g. isoniazid).
- Poly-resistance: resistance to more than one type of drug (e.g. streptomycin, isoniazid and ethambutol).
- MDR-TB: this is a subcategory of poly-resistance. TB resistant to at least isoniazid and rifampin.
- Extremely drug-resistant tuberculosis (XDR-TB): this is a subcategory of MDR-TB. XDR-TB is defined as MDR-TB plus resistance to a quinolone and an injectable second-line drug (kanamycin, capreomycin etc.)

Tuberculosis that is sensitive to all drugs is called pansusceptible TB.

Depending on the way resistance is required, two types are distinguished:

- Acquired or secondary resistance; this is defined as resistance to one or more anti-TB drugs, which arises during the course of treatment, usually due to non-adherence to the recommended regimen or due to incorrect drug prescription and intake.
- Primary resistance. This is defined as the presence of resistant strains of *M. tuberculosis* in patients, who have been infected with resistant bacilli by another patient and subsequently develop the disease.

Depending on the treatment history, two types of resistance are distinguished:

- Resistance among new patients, i.e. patients who were never treated before or were treated for maximum one month;
- Resistance among retreatment patients.

10.4 Magnitude of MDR-TB in Bangladesh

There are no national data on drug resistance in Bangladesh. However, in collaboration with Shyamoli CDC, the International Centre for Diarrheal Diseases and Research, Bangladesh has conducted drug-susceptibility testing in a sample of 657 patients showing 3% and 15% MDR-TB among new and previously treated TB patients, respectively.\(^2\) These data are not representative since Shyamoli CDC is a referral centre. Damien Foundation has also conducted two drug-resistance studies in 1995 and 2001 comprising 645 and 1041 patients. The 1995 study showed 0.7% and 6.8% MDR-TB

among new and previously treated TB patients, respectively\(^3\); the 2001 study showed 0.4% and 3% MDR-TB among new and previously treated TB patients, respectively\(^4\). A study conducted in 2005-2006 showed that of 96 Category II failures, 88% had MDR-TB.\(^5\)

Although the rates of MDR-TB in Bangladesh do not appear to be high, these low rates still translated into a high absolute number in view of the high burden. According to the WHO report 2008, the MDR-TB rate in Bangladesh is estimated at 3.6% and 19% among new and previously treated TB cases, respectively.

10.5 The operational manual

The NTP has published a separate manual for the management of drug-resistant tuberculosis. The guidelines expand upon the most recent WHO guidelines on TB\(^6\), which included specific considerations for chronic and MDR-TB cases. The term DOTS-Plus has been currently used to refer to the management of drug-resistant TB building on basic DOTS programmes.

Category II failures will be referred by the medical officer of the Upazila Health Complex (and other health care facilities) to NIDCH. Patients residing in areas supported by Damien Foundation will be referred to the Damien Foundation hospitals in Tangail (Jalchatra), Mymensingh, Netrakona or the Faridpur TB hospital. Patients from Rajshahi division will be referred to the Rajshahi Chest Diseases Hospital.

**Referral flow chart**

---


5 NTP-NIDCH study (2005-06) to assess drug resistance pattern among category 2 failure patients. Laboratory tests were done in Antwerp SRL.

6 For more information see the Green Light Committee web page at http://www.who.int/tb/dots/dotsplus/management/en/
Inclusion criteria for case finding and treatment

The National TB Control Program has published detailed and separate MDR-TB guidelines.
11. INFECTION CONTROL

Transmission of TB is a recognized risk in health care facilities and communities, especially in resource-limited settings where transmission is facilitated by inadequate TB infection control measures. TB infection control has three components. By order of importance, they are as follows: administrative controls, environmental controls and personal respiratory protection.

11.1 Components of Infection Control

a. Administrative controls

The administrative controls include policies and procedures intended to promptly identify and treat infectious cases so that additional precautions can be taken. An important aspect of administrative control measures is the physical separation of patients known or suspected of having TB or MDR-TB (especially smear-positive cases) from other patients.

b. Environmental controls

In warm climates, infection control can be assured most effectively by strong natural ventilation (i.e. open windows in opposite walls).

c. Personal respiratory protection (special masks)

In addition, when administrative and environmental controls cannot provide complete protection, the third line of defense against nosocomial TB transmission is the use of masks. Because they are visible and relatively expensive, health workers assume that supplying personal masks alone will prevent TB transmission. However, they cannot be worn continuously and are likely not to be in use when unsuspected TB cases, or unsuspected MDR-TB, is encountered. Staff protection can be assured only by masks with a high-efficiency air-intake filter, and fitting tightly around the face so that no air can come in from besides the mask.

Patients will also wear personal masks to minimize dispersal of bacilli when they talk, cough, yawn or sneeze. These can be simple surgical masks; they will retain the droplets expelled by the patient effectively.

In addition to the above, basic infection control measures will be taught to patients such as covering the nose and mouth during coughing and sneezing and to discard used tissue into covered bins.

11.2 Essential Actions for Effective TB Infection Control Safety without stigma

1. Include Patients and Community in Advocacy Campaigns

The community should be well-educated about TB infection, prevention and control. Patients should understand that they should know their TB status and have a right to rapid TB diagnosis and treatment. They should know that TB can be spread by coughing and expect health care settings and community services to require persons coughing to cover their mouths when coughing. They should understand that health care workers (HCWs) may wear personal respiratory protection sometimes or that they
may be asked to wear a mask to protect others. Safety without stigma should be the
goal--a request to wear a mask or provide sputum outside, or in a well ventilated room
should not be stigmatizing but is part of a safer clinic for everyone.

2. Develop an Infection Control Plan

   All facilities should have an infection control (IC) plan and a facility person or team
   responsible for IC.

3. Ensure Safe Sputum Collection

   Collecting and processing sputum are an essential part of the diagnosis of TB.
   Sputum collection can be potentially hazardous for health care workers and other
   patients--HCWs should explain to patients that safety without stigma is the goal of good
   TB infection control and that sputum be collected outside.

4. Promote Cough Etiquette and Cough Hygiene

   Every facility should have a poster on TB infection control and cough etiquette in at
   least the outpatient department waiting area, admissions area, and casualty department.
   Patients should be instructed to cover their mouths and nose when coughing, with
   hands, cloth such as handkerchief, clean rag, tissues, or paper masks.

5. Triage TB suspects for "fast-track" or separation

   All patients should be screened upon arrival for chronic cough (i.e. >3 weeks), fever,
   weight loss, night sweats, haemoptysis, or contact with a person with TB. Persons
   suspected of having TB should be "fast-tracked" for rapid diagnosis and care services or
   should be asked to wait near an open window or in a comfortable area separate from
   the general waiting room (outside when possible). Community-based treatment models
   should be encouraged. Where there are in-patient settings, TB suspects should be
   placed in a room or area separate from general wards. Patients with known or
   suspected drug-resistant TB should be separated from general ward patients and from
   other TB suspects.

6. Assure Rapid Diagnosis and Initiation of Treatment

   Patients suspected of having TB should move to the front of the queue for all
   services and should undergo prompt evaluation for TB. Sputum collection should be
done away from other people. Sputum specimens are sent to a quality-assured
labatory for AFB smear. A patient-tracking system assures that TB suspects who are
AFB smear-negative receive additional procedures (e.g. chest x-ray and referral visits)
or treatment as quickly as possible. DOTS treatment for TB begins immediately when a
diagnosis of TB is made.

7. Improve Room Air Ventilation

   Patient waiting areas should be open and well-ventilated. Windows and doors
   should remain open when possible, to maximize cross ventilation. Appropriately placed
   simple fans can assist ventilation. Where weather permits, open-air shelters with a roof
to protect patients from sun and rain are recommended. Patients should not wait for services in narrow, poorly ventilated corridors. Hospitals where patients with drug-resistant TB receive care should provide separate patient wards or rooms, preferably with good ventilation.

8. **Protect Health Care Workers**

   Health care workers should know the symptoms of TB.

9. **Capacity Building**

   Training on TB infection control practices should be incorporated into the broader infection control trainings at hospitals and facilities (e.g. hand washing, other respiratory, and bloodborne infection control trainings).

10. **Monitor infection control practices**

    Supervision of infection control practices should be a part of every supervisory visit. On-site measures include examining medical records of a sample of TB patients looking at the time interval from admission to suspicion of TB, suspicion of TB to ordering sputum for AFB, time from ordering to collection of sputum, collection of sputum to reporting of results, to initiation of TB treatment and interviewing patients to discuss understanding of infection control, safety and stigma.

(These ten essential actions are based on current WHO policy: http://www.who.int/topics/hiv_aids/en/ or http://www.stoptb.org/wg/tb_hiv/tbics.asp for more information).
12. TB-HIV CO-INFECTION

12.1 Definition: TB/HIV co infection denotes two diseases in one body

There is a positive co-relation between TB incidence and HIV prevalence. Generally, the lifetime risk of developing active TB is around 10 percent while for TB/HIV co infection the risk is around 60 percent. HIV is the most powerful known risk factors for reactivation of latent tuberculosis to active disease. HIV infected people are most susceptible to be TB when they are exposed to Mycobacterium Tuberculosis, HIV increase the rate of recurrent TB, TB-HIV cases poses an increase risk of TB transmission to the general community, whether or not HIV infected. The estimated TB/HIV co-infection is 0.1% according to the study done on a sample of 1000 patients in Dhaka. Although the data show, by now, a low HIV prevalence in TB patients while the TB prevalence in PLHIV is high, the country situation with its 50% of population infected by TB called for a rationale for collaboration between TB and HIV activities. Considering the facts, functional collaboration has been established between NTP and NASP for implementing the collaborative TB/HIV programmes.

According with the WHO guidelines and the Bangladesh country profile, Bangladesh is classified in category 2 in TB/HIV collaboration model for two reasons: the national country adult HIV prevalence is below 1% & there is area with adult prevalence rate higher than 1%. According to this criteria TB/HIV activities need to be established as TB/HIV Co-infection burden in different administrative and geographic setting. In national context to identify the trend of TB/HIV co-infection burden and to design the activities National Survey for TB in HIV patient to be done 2-3 yearly. Considering all facts a country specific National Guideline on TB/HIV Programme Collaboration has been developed.

12.2 Goal of TB/HIV strategy

The goal of the TB/HIV strategy is to reduce TB/HIV associated morbidity and mortality through collaboration between National AIDS Programme and National TB programme.

12.3 The objectives of TB/HIV strategy are:

1. To establish the mechanism for collaboration between tuberculosis and HIV/AIDS programmes.
2. To decrease the burden of TB among People Living with HIV (PLHIV) and
3. To decrease the burden of HIV in TB patients.

12.4 Strategies to achieve the goal and objectives are:

1. Establish a joint surveillance mechanism to assess the annual status of TB/HIV
   - Assess annual status of HIV among TB patients by routine HIV screening among TB patients as set criteria.
   - National HIV sero prevalence in TB patients 2– 3 yearly.
   - Yearly TB screening for PLHIV (Sputun & CXR )
2. Prevention, Control & Management of TB/HIV Co-infection.
   - Building the capacity of service providers
   - Strengthening of Counseling
   - Ensure logistics
12.5 Strategy for implementation

- Functional collaboration and not structural programme integration
- Integration into ongoing programmes; and the need to generate evidence in order to effectively respond to TB/HIV in a comprehensive manner
- This collaboration should be based on well-defined responsibilities and the complementary nature of each programme;

12.6 Criteria for TB/HIV Referral

From VCT to DOTS:
1. All HIV positive patients
2. Suspected TB cases among the high risk group
3. Immediate family / partners contacts of HIV positive patients.

From DOTS to VCT:
1. TB with history of high risk behavior (IDU, unsafe blood transfusion, SW, migrant workers, H/O STI, MSM, transgender/ Hijra)
2. TB suspects with history of high risk behavior (IDU, unsafe blood transfusion, SW, migrant workers, H/O STI, MSM, transgender/ Hijra)
3. Complicated extra-pulmonary TB, Relapse and treatment failure Cases,
4. MDR-TB
5. Clinical suspects of HIV infection
6. Children of mothers known to be HIV-positive
7. Others

12.7 Mechanism for TB/HIV Referral

From VCT to DOTS:
- Patient to go with existing referral card
- Sputum collection if patient can not go with Sputum Request Form

From DOTS to VCT:
- Patient to go with referral card

What to do when HIV patient is suspected as TB

- Always refer TB suspects to nearest DOTS centre for diagnosis of TB.

What to do if HIV patients are diagnosed of having TB

- VCT focal person should communicate with responsible person at TB-HIV partner organization or DOT centre for anti-TB drugs and arrange for collection anti-TB drugs.
- Ensure daily intake of anti-TB drugs (DOT) and recording in treatment card at VCT centre
- Enquire for any possible side effects of anti-TB drugs
- Encourage for regular treatment
- Refer the patient timely for follow-up to the DOT centre and whenever side effects of drugs is suspected
- Discharge patient from treatment at end of the course, refer to DOT centre for final examination and provide required information (copy of treatment card) to DOT centre

12.8 Diagnosis and Management of TB/HIV Co-infection:

Described in National Guideline on TB/HIV Programme Collaboration.

12.9 Monitoring, Supervision and Reporting:

Exiting Programme will be responsible for TB and HIV as individual disease as existing programme M&E and supervision framework.

Patient after diagnosis as TB/HIV Co-infection will be managed and reported by VCT center but effective co-ordination between DOTS and VCT center to be maintained.

Joint M & E Plan will be done by NTP and NASP.

Some TB/HIV indicators has been included in NTP revised MIS.

(Note: For detail understanding review “National Guidelines on TB/HIV Program Collaboration”)
13. PUBLIC-PRIVATE MIX (PPM) FOR TB CONTROL

Public-Private Mix is a strategy, which aims to link the resources of public and private health care providers to achieve national TB Control targets.

Given the Bangladesh context, where private practitioners constitute a large proportion of the service delivery infrastructure and where almost half the people seek care for chest-related problems from the private sector, it is important that they are an integral component in the delivery of TB services under the umbrella of the NTP. It is widely recognized that the quality of and access to health care provision can be greatly enhanced by involvement of all health care providers through PPM. The combined efforts of the public and private sector are critical for Bangladesh in order to help halt the TB burden. The private sector resources can be best utilized to cover DOTS in these areas.

Many private providers in Bangladesh are already providing services to TB patients. However, the TB management practices in the private sector are not standardized and the precise number of TB cases detected and treated in the private sector is not known. This is due to the lack of sufficient interaction and formal linkages between NTP, private, NGO and public sector providers. Their involvement in the delivery of services will enable provision of high quality and effective TB services by all care providers.

13.1 The PPM approach for TB Control in Bangladesh are of various forms, such as:

1. Public with Private (for example: NTP collaborating with NGOs and private sector);
2. Public with Public, (for example: NTP collaborating with Defense, Police Health Services etc.); and
3. Private with Private health care providers (for example: NGOs working with Private Practitioners)

13.2 Current and Potential Providers for PPM:

Institutional Providers:

a. National TB Control Programme
b. City Corporation Health Services
c. NGO partners
d. Academic Medical Institutions e.g.: Medical Colleges, Specialized Institutions and Universities
e. Other Government Hospitals e.g.: District Hospitals, Upazila Health Complexes and Chest Hospitals etc.
f. Corporate Sectors/Work Places e.g.: Export Processing Zone (EPZ), Port, Railway, garments, knitting and other companies etc.
g. Prison Health Services
h. Defense/ Police Medical Services
i. Private Hospitals and Clinics/ Private laboratories
j. Pharmacies/drug sellers

Individual Providers:

a. Specialist Physicians
b. Graduate Private Practitioners (PP’s)
c. Non-graduate PPs e.g.: Sub-assistant Community Medical Officer (SACMO), Medical Assistant, Practitioners with LMF (Licentiate Medical Faculty) and MFPC (Member of the Faculty of Polli Chikitsok) etc.
d. Non-qualified PPs e.g.: Village Doctors
e. Community Health Volunteers e.g.: Shastho Shebika, Cured TB Patient, etc.

13.3 Roles of Diverse PPM Partners:

a. NTP:
   - Central level planning for PPM for TB Control;
   - Developing and distribution of PPM guidelines and training modules;
   - Training of trainers;
   - Developing and distribution of advocacy materials;
   - Providing drugs and logistic supplies;
   - Supervision and monitoring
   - Recognition of high performing partners

b. Implementing Partners:
   - Local level planning for PPM;
   - Training;
   - Establishing successful linkages among providers;
   - Providing free sputum smear microscopy and drugs for TB patients;
   - Organizing delivery of DOT;
   - Recording and reporting;
   - Supervision and monitoring

Contractual tools will be used such as a Memorandum of Understanding (MoU) to formalize partnership between Institutional providers and the NTP or a Letter of Agreement (LoA) to establish effective linkages with individual providers. These tools will be drafted through mutual consensus and are expected to clarify the expected roles and responsibilities of the collaborating partners.

The National TB control program has published PPM guidelines for TB Control and details of PPM TB Control are available in its guidelines.
14. ADVOCACY, COMMUNICATION AND SOCIAL MOBILIZATION (ACSM)

Tuberculosis is a social disease with a medical aspect. It is regarded as a barometer of social welfare. It is a public health problem worldwide. One third of the world population is infected with TB. Bangladesh ranks 6th among 22 high burden countries. ACSM activities are essential for the effective TB Control in Bangladesh.

Advocacy

The activities designed to place high in the political and developmental agenda. It will deal with political will and will increase the financial and other resources in a substantial basis. NTP is conducting the advocacy in the ministry, directorate and in the different policy level as routine activities. To cover TB related topics regularly and in a responsive manner for generating support from governments and donors advocacy is also conducted with the media people.

Communication

It is a theme expressing the process used by the people to exchange information's, views and opinions within each other. It is a two way process involving participation and dialogue as key element to change behavior of the specific group of people. In general people are not well informed regarding the symptom of TB, the mode of spread and personal hygiene. They do not know that the TB is curable, the treatment of TB is free of cost and the service providing all over the country by DOTS strategy. Maximum effort is going on in communicating the target group of people by NTP through arranging communication meeting and/or through with the help of NGO partners wherever feasible.

Social Mobilization

Social mobilization is the process of involving and motivating interested stakeholders (general population, health workers, policy makers etc.) to organize and take action for a common purpose to assist in the delivery of resources and services to strengthen community participation for sustainability and self-reliance. The aims of social mobilization are to bring about a social change within the country and to build up partnership. NTP is now working with more than thirty NGOs in the TB control activities to achieve the common goal.

ACSM helps in the TB control process by improving case detection and treatment adherence, combating stigma and discrimination, empowering people affected with TB and mobilizing political commitment and resource for TB.

NTP has developed for distribution of substantial amount of IEC material for enhancing ACSM activities to aware the high risk, marginalized and difficult to reach population.
Job Description (TB)  

Area : DGHS  
Sub area : Tuberculosis  
Post : Civil Surgeon  
Location : Civil Surgeon Office  
Supervisor : Divisional Director/ Line Director/Program Manager  

Responsibilities:

(1) Supervise the overall coordination procedure of NTP in the relevant geographic area;

(2) Supervise and provide technical support for quality assured laboratory networks and standard diagnostic facilities of NTP service delivery through government and partners and support NTP in sustaining and enhancing DOTS to reach all TB patients;

(3) Ensure that Government Medical Technologist performs AFB microscopy;

(4) Supervise and provide technical support to ensure anti-TB treatment according NTP guidelines including Directly Observed Treatment;

(5) Supervise and provide technical support for proper recording of patients and updating of TB registers to ensure improved case detection and treatment success;

(6) Supervise, coordinate and monitor management of MDR-TB with the National Institute of Diseases of Chest and Hospital and DOT provider center;

(7) Coordinate and supervise TB-HIV collaborative activities as when available in the district;

(8) Supervise and monitor public-private partnership by involvement of private, corporate, defense, prisons and other relevant sectors in TB control within the geographic locations;

(9) Conduct regular quarterly meetings on DOTS and expanded DOTS activities and monitor NTP performance and advise corrective measures for TB control;

(10) Supervise proper procurement, storage and distribution of anti-TB drugs;

(11) Supervise and provide technical support for in-service training to relevant staff providing NTP services;

(12) Supervise Advocacy, Communication and Social Mobilization activities for awareness building and to increase case detection and treatment success rate;

(13) Coordinate and Supervise the referral of Suspect and provision of DOT by Government field staff.
Job Description (TB)  
Annex 1-B

Area: DGHS  
Sub-area: Tuberculosis  
Post: Junior Consultant Chest Clinic  
Location: CDC  
Supervisor: Civil Surgeon

Responsibilities:

1. Overall coordination of activities for NTP in the relevant geographic area;

2. Coordinate quality assured laboratory networks and standard diagnostic facilities of NTP service delivery through government and partners;

3. Support NTP in sustaining and enhancing DOTS to reach all TB patients;

4. Ensure identification of TB suspects and diagnosis of TB especially Smear Negative, Extra pulmonary and Child TB according to the NTP guidelines;

5. Ensure treatment according to the NTP guidelines, including directly observed treatment;

6. Coordinate, supervise and monitor management of MDR-TB, TB-HIV collaborative activities in line with National Guidelines;

7. Ensure proper records of the patients under treatment and assist in updating registers of the tuberculosis patients;

8. Assist and ensure tracing of defaulting TB patients and resumption of their treatment through government and partners;

9. Ensure clinical progress, identify and treat adverse reactions to drugs and manage complicated cases when and where necessary;

10. Ensure regular supply of Anti-TB Drugs and other logistics including ACSM material;

11. Assist and ensure accurate NTP quarterly reporting, quarterly monitoring of NTP performances and appropriate corrective action towards TB control;

12. Organize and facilitate in-service training to necessary staff, which addresses NTP services;

13. Ensure appropriate public-private partnership by involving corporate, defense, prisons and other relevant sectors for TB Control Programme;

14. Assist and ensure ACSM activities to individuals and community to promote self-reporting and treatment compliance of TB patients;

15. Ensure, Perform and monitor regular supervision of NTP activities at the relevant levels.
Job Description (TB)  
Annex 1-C

Area: DGHS  
Sub-area: Tuberculosis  
Post:  
(1) Upazila Health & Family Planning Officer (UHFPO)  
(3) Medical Officer TB/Leprosy (MO TB/LEP) Designated  
(4) Medical Officer Chest Disease Clinic  
(5) Medical Officer Disease Control (MO DC)  
(6) Medical Officers, NGOs  

Location: Civil Surgeon’s Office/Chest Disease Clinic/Upazila Health Complex  
Supervisor: Civil Surgeon  

Responsibilities:

1. Overall coordination of activities for NTP in the relevant geographic area;  

2. Coordinate and ensure quality assured AFB Microscopy by Government Medical Technologist and standard diagnostic facilities of NTP service delivery through government and partners and support NTP in sustaining and enhancing DOTS to reach all TB patients;  

3. Assist and ensure treatment according to the NTP guidelines, including directly observed treatment;  

4. Assist and ensure proper records of the patients under treatment and update registers of the tuberculosis patients by TLCA/assigned TLCA to ensure improved case detection and treatment success;  

5. Assist and ensure tracing of defaulting TB patients and resumption of their treatment involving Govt. field staff;  

6. Ensure referral of suspect and provision of DOT by Government field staff  

7. Ensure clinical progress, identify adverse reactions to drugs and refer the TB patient for proper management when necessary;  

8. Coordinate, supervise and monitor management of MDR-TB, TB-HIV collaborative activities in line with National Guidelines  

9. Ensure appropriate public-private partnership by involving corporate, defense, prisons and other relevant sectors for TB Control Programme;  

10. Ensure accurate NTP quarterly reporting, quarterly monitoring of NTP performances and appropriate corrective action towards TB control;  

11. Ensure in-service training to necessary staff, which addresses NTP services;  

12. Assist and ensure ACSM to individuals and community to promote self-reporting and treatment compliance of TB patients;  

13. Assist and ensure regular supervision of NTP at the relevant levels.
Job Description (TB)  

Annex 1-D

Area: DGHS

Sub-area: Tuberculosis

Post: Programme Organizer

Location: Civil Surgeon Office

Supervisor: Civil Surgeon

Responsibilities:

1. Supervise NTP performance in the field level and assist in implementation of TB control measures;

2. Assist and ensure proper registration, recording and reporting of TB patients by LTCA and take appropriate measures to take corrective actions as when required;

3. Assist to conduct regular quarterly monitoring meetings on DOTS, prepare meeting minutes, submit to Civil Surgeon for distribution and assist to execute recommendation of QMM up to field level;

4. Assist and ensure regular supply of Anti-TB Drugs and other logistics including ACSM material;

5. Assist and ensure proper display of ACSM material to all DOT centres and update the TB related information in the display board;

6. Assist in coordination with NGOs and other private sectors for implementation of DOTS;

7. Assist and organize awareness building activity to the community to promote self-reporting and treatment compliance of TB patients.
Job Description

Area: DGHS
Sub-Area: Tuberculosis
Post: Medical Technologist (Laboratory)
Location: Upazila Health Complex, Hospitals, Clinics (GoB, NGOs)
Supervisor: Jr. Consultant, Chest Disease Clinic
Chief Medical Technologist (Laboratory), Civil Surgeon Office
Medical Technologist (Laboratory) Chest Disease Clinic (lab)
TB/Leprosy Programme Organizer
MO TB/Leprosy (Designated) of the District

Responsibilities:

1. Maintain essential safety precautions during sputum collection, while working in the lab and concerning disposal of potentially infectious materials;

2. Collect sputum samples from suspects and patients on TB treatment:
   2.1 Explain the sampling procedure to the patient;
   2.2 Issue sputum containers and demonstrate how to use them;
   2.3 Give a unique identification number to each sample.

3. Prepare and examine a smear from each sputum sample submitted; prepare and examine smear from the types of a samples if requested by a medical officer:
   3.1 Properly identify a slide for each sample;
   3.2 Make a smear, fix and stain the smear;
   3.3 Examine the smear microscopically.

4. Record results of smear examinations and report them promptly to the requesting staff record results on sputum examination request form and TB laboratory register transmit positive results without delay;

5. Assure proper storage and regular supply of reagents and other materials :
   5.1 Store stains, sputum containers and slides protected from damage by light, dust or humidity;
   5.2 Timely request or collect appropriate quantities of supplies.

6. Monitor sputum smear results periodically for internal quality control; keep smears for re-checking:
   6.1 Periodically count numbers of results from the TB laboratory register;
   6.2 Note these counts in the register and calculate and plot positively rates;
   6.3 Preserve all slides after examination till a sample for re-checking is taken.

7. Keep the microscope as well as the laboratory in proper condition
   7.1 Clean the microscope regularly and take precautions against damage;
   7.2 Keep the laboratory neat and tidy;
   7.3 Transmit any problems with the microscope or other equipment to the appropriate authority.
Job Description (TB)  

Area: DGHS

Sub-area: Tuberculosis

Post: Health Inspector (HI)  
Assistant Health Inspector (AHI)  
Family Planning Inspector (FPI)  
Health Assistant (HA)  
Medical Assistant (MA)  
NGO Community Health Workers

Location: UHC/ Union Health & Family Welfare Center (UHFWC)

Supervisor: UH&FPO/Medical Officer of UHFWC

Responsibilities:

1. Supervise the proper execution of all the tasks listed against each posts;

2. Assist and ensure the referral of symptomatic and TB patients;

3. Assist and ensure the directly observed treatment in the community and the tracing of TB treatment defaulters;

4. Assist and ensure proper registration, recording and reporting of TB patients;

5. Assist in collaborating public-private sectors;

6. Assist and ensure adequate and timely supply of anti-TB drugs and other items;

7. Assist and organize awareness building activity to the community to promote self-reporting and treatment compliance of TB patients.
Job Description (TB)  

Area: DGHS  
Sub-area: Tuberculosis  
Post: Leprosy and TB Control Assistant (LTCA)  
Location: Upazila Health Complex  
Supervisor: UH&FPO

Responsibilities:

1. Perform the activities for NTP in the relevant geographic area;
2. Support standard diagnostic facilities of NTP service delivery through government and support NTP in sustaining and enhancing DOTS to reach all TB patients;
3. Assist treatment according to the NTP guidelines, including directly observed treatment;
4. Maintain proper records of the patients under treatment and update registers of the tuberculosis patients;
5. Assist tracing of defaulting TB patients and resumption of their treatment involving Govt. field staff;
6. Assist and ensure referral of suspect and provision of DOT;
7. Identify adverse reactions of drugs and refer the patient to UH&FPO/ MO DC for proper management;
8. Assist appropriate public-private partnership for TB Control Programme;
9. Prepare NTP quarterly reports including Lab performance and submit to UH&FPO timely;
10. Prepare reports of NTP performance for Upazila monthly meeting and District Quarterly meeting
11. Prepare indent for anti-TB drugs and other requirements with the help MODC and submit to UH&FPO;
12. Ensure display and proper use of available NTP ACSM material and collect the required material from NTP
13. Ensure display of update TB related information in the Upazila display board
14. Assist in implementing ACSM activities in the community to promote self-reporting and treatment compliance of TB patients;
15. Perform regular supervision of NTP activities at the field level.
16. Maintain liaison with NGOs and other partners in the field level.
Area : DGHS
Sub area : Tuberculosis
Post : Statistical assistant
Location : Civil Surgeon Office
Supervisor : Civil Surgeon

Responsibilities:

1. Collection of quarterly report (case finding, treatment outcome, sputum conversion & lab report) from Upazilla Health Complexes of the respective district.
2. Compilation of collected quarterly report.
3. Sending quarterly report to NTP Head quarter after getting signature from C/S.
4. Entering upazillawise TB related data at the district using TB Data management program.
5. Processing, Analysis & Interpretation of data at district level.
6. Preparation of quarterly report of respective district with chart and table.
7. Preparing and displaying graphical presentation of sharing time trends of some basic indicators (case finding, treatment outcome, No of TB suspect tested, No of positive case found, case positivity rate.)
### NATIONAL TUBERCULOSIS CONTROL PROGRAMME

** Direcotive General of Health Services, Bangladesh**

**Tuberculosis Treatment Card (Front page)**

| Name: | |
| Date: | |
| Name & Address of: | |
| Health Institution / DOT Center: | |
| TB Registration No: | |
| Disease Classification: | Pulmonary | Extra pulmonary |
| Sex: M [ ] F [ ] | **** | |
| Age: | BCG: no scar | scar seen | |
| Name and address of person providing DOT: | |
| *Ref by: | PP [ ] Govt. Hospital | SS [ ] GFA | TB Patient [ ] |
| | |
| I. INTENSIVE PHASE: Prescribed regimen and dosages |
| Frequency: Daily |
| Tick category and indicate number of tablets per dose and doses of (Signs) |

| CAT 1 | CAT 2 | Child |
| 4FDC | 4FDC | |
| 3FDC | E | |

R H Z E R H Z E S R H Z E S

Enter [ ] in the appropriate box to indicate the date when the drugs have been swallowed under direct observation:

<table>
<thead>
<tr>
<th>Month / Year</th>
<th>Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

**Tuberculosis Treatment Card (Back page)**

II. CONTINUATION PHASE: Prescribed regimen and drug dosages

Put tick [ ] mark in the appropriate box:

| CAT 1 | CAT 2 | Child |
| 2FDC | 2FDC | E |
| R | H | R | H |

Enter a tick [ ] in the appropriate box to indicate the date when the drugs have been swallowed under direct observation:

<table>
<thead>
<tr>
<th>Month / Year</th>
<th>Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

**Treatment outcome**

- Curad
- Treatment completed
- Died
- Treatment failure
- Default
- Transfer out

**Remarks:**

Signature of Medical Officer

---

* PP = Private Graduate Practitioner, GFS = Government fellow staff, Non PP = Non Private Graduate Practitioner, SS = Shastho Shiksha, VO = Village Doctor, CV = Community volunteer

Signature of Medical Officer
## NATIONAL TUBERCULOSIS CONTROL PROGRAMME

**Directorate General of Health Services, Bangladesh**

**Tuberculosis Register (Left side)**

<table>
<thead>
<tr>
<th>Date of Registration</th>
<th>TB Registration No</th>
<th>Name in full</th>
<th>Sex</th>
<th>Age</th>
<th>Occupation</th>
<th>Address in full</th>
<th>Name of Treatment unit</th>
<th>Date of start of treatment and regimen</th>
<th>Disease classification PEP</th>
<th>Type of patient*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**TB 03**

**Notes:**

- **Enter the appropriate code:**
  
  **N:** New case: a patient who has never taken tuberculosis drugs or has taken drugs for less than a month
  
  **R:** Relapse: a previously treated patient, who was declared cured, but is now smear-positive again
  
  **T:** Transfer in: a patient, who has been transferred from one reporting unit to another. For transfer in patient name of the center from where patient was transferred should be written in the remarks column.
  
  **D:** Treatment after interruption: a patient who returns to treatment after having interrupted treatment for two consecutive months or more having treatment for 1 months or more
  
  **F:** Treatment failure: a smear-positive patient who remained, or became again, smear positive at five months or later after commencing treatment or a sputum negative patient became smear positive at 2 months.
  
  **O:** Other: patients, who cannot be classified to any previous category.
### NATIONAL TUBERCULOSIS CONTROL PROGRAMME

**Directorate General of Health Services, Bangladesh**

**Tuberculosis Register (Right side)**

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Follow-up smear</th>
<th>Date</th>
<th>Outcome</th>
<th>HIV Result Date</th>
<th>ART ON Start date</th>
<th>CPT ON Start date</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear 1</td>
<td>Smear 2</td>
<td>Smear 3</td>
<td>X-ray/ 2nd 3rd/4th Treatment</td>
<td>6th month 6th/8th month</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Enter date in the appropriate column:**

1. Cured: Treatment completed and negative smear results on 2 or more consecutive occasions at 5 months and at the end of the treatment.
2. Treatment completed: Full course of the completed list sputum result is not available for continuation phase.
3. Died: Patient known to have died from any cause during treatment.
4. Failure: Smear-positive at 5 months or later for CAT 1 and at 2 months for CAT II.
5. Treatment after interruption (Default): Patient who has not collected drugs for 2 months or more.
6. Transferred out: Patient who has been transferred to another DOT Centre. Name of Center from where the patient was transferred out should be written in the remarks column.

---

### NATIONAL TUBERCULOSIS CONTROL PROGRAMME-BANGLADESH

**Tuberculosis Laboratory Register**

<table>
<thead>
<tr>
<th>Lab Serial No.</th>
<th>Date of specimen received</th>
<th>Name in full</th>
<th>Address in full (patients for diagnosis)</th>
<th>Occupation</th>
<th>Age</th>
<th>Sex</th>
<th>Name of treatment/ referring facility</th>
<th>Reason for examination</th>
<th>Result of Smear Examination</th>
<th>TB registered no. (after registration)</th>
<th>Referred by **</th>
<th>Signature</th>
<th>Remarks</th>
</tr>
</thead>
</table>

**Enter TB Register Number & month of follow-up:**

**PP= Private Practice Practitioner, GFS= Government field staff, Non PP= Non Private Practice Practitioner, SS= Shastha Shiksha, VD= Village Doctor, CV= Community Volunteer, Gov. Hospital, Private Hospital, TB Patient, Other (specify)**

---

72
NATIONAL TUBERCULOSIS CONTROL PROGRAMME (NTP)
Directorate General of Health Services, Bangladesh
Request Form for AFB Microscopy Examination
(The completed form with results should be sent promptly by the Laboratory to the referring facility)

Name of Referring Facility/Providers: ____________________________ Date: ____________________________

Name of Patient: ____________________________ Age: ____________ Sex: □ M □ F

Occupation: ____________________________ Name of Father/Husband: ____________________________

Full Address of Patient: __________________________________________ Telephone no. (if any): ____________________________

OPD Reg. No. (if any); (For suspects only): ____________________________

Reason for examination: □ Diagnosis □ Follow-up □ If follow-up, No. of month of Treatment: ____________________________

Disease Classification: □ Pulmonary □ Extra-pulmonary (EP) □ If EP, Site: ____________________________

Nature of Specimen: □ Sputum □ Urine □ Pus □ Other, specify: ____________________________

Specimen identification no: ____________________________ Patient TB Registration No: ____________________________ (For follow-up patients)

Signature of person requesting examination: ____________________________

Name & designation of person requesting examination: ____________________________

1. Including all public and private health facility/providers

RESULTS (To be completed in the Laboratory)

Lab Registration No: _____________________________________

Visual appearance of the specimen (if it is sputum): □ Muco-purulent □ Blood-stained □ Saliva

Microscopy results

<table>
<thead>
<tr>
<th>Date of Collection*</th>
<th>Specimen</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Negative</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sputum collected by: ____________________________

Signature: ____________________________

Name: ____________________________

Examined by: ____________________________

Signature of Medical Tech (Lab): ____________________________

Name: ____________________________

Date: ____________________________

Name of Lab/Organization: ____________________________

* To be completed by the person collecting the sputum
NATIONAL TUBERCULOSIS CONTROL PROGRAM
Directorate General of Health Services, Bangladesh
Tuberculosis Culture/Sensitivity Test Request/Report Form

(1) Patient TB Registration No: __________________________ District: __________________________
Name of patient: __________________________ Hospital: __________________________

(2) Please (✓) mark in appropriate box

☐ Failure after CAT-II Regimen  ☐ Relapse after CAT-II Regimen

Previous history of Treatment:
Chemotherapy given:

<table>
<thead>
<tr>
<th>Drug</th>
<th>From</th>
<th>To</th>
<th>From</th>
<th>To</th>
<th>From</th>
<th>To</th>
<th>From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptomycin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampicin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethambutol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyrazinamide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Date: __________________________ Name of MO __________________________
Send results to (Address): __________________________

(3) Specimen(s) of Sputum at 0 Month: __________________________
(Please tick):

☐ 2 Months  ☐ Other Specimen Specify: __________________________
Patient Starts/Started Treatment on: __________________________
End of Treatment: __________________________
Date(s) of sputum collection: __________________________

(4) FOR LAB USE ONLY

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Results*</th>
<th>Positive (grading)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>3+ 2+ 1+ scanty (1-9)</td>
</tr>
</tbody>
</table>

Lab. Serial No: __________________________
Direct Smear: __________________________

*Write Neg. or pos.

(5) **SENSITIVITY TESTS

<table>
<thead>
<tr>
<th>DRUG</th>
<th>SENSITIVE</th>
<th>RESISTANT</th>
<th>COMMENTS:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptomycin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampicin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethambutol</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Not done at 2 months
Date: __________________________ Lab. Signature: __________________________
NATIONAL TUBERCULOSIS CONTROL PROGRAM CENTRE
Directorate General of Health Services, Bangladesh

☐ TB Referral form  ☐ TB Transfer form
(Put tick ☑ mark in the above appropriate box)

(fill out in triplicate with carbon paper between sheets)
Name of Referring/Transferring Unit: __________________________ Phone: __________________
Name of Institution to where patient is referred (if known): _______________

Name of patient: __________________________ Age: ____________ Sex: ____________
Address (In full): __________________________

TB Registration No: __________________________ Date of Treatment started: __________________________
Type of Treatment: __________________________
☐ CAT 1 New smear positive
☐ CAT 2
☐ Child
☐ New Case (smear-negative EP)
☐ Others: __________________________

Date of treatment started: __________________________
No. of days which patient received drugs at least attendance
Reasons for referral: __________________________
Remarks: __________________________
Signature: __________________________
Designation: __________________________
Date referred/transferred: __________________________

For use by the Institution where the patient is referred to send outcome report to the institution
where patient was initially registered

Name of patient: __________________________ TB Registration No: __________________________
Age: ____________ Sex: ______ M ☑ F ☑
TB Registration no (of the organization from where the patient was referred): __________________________
Treatment result: __________________________
☐ Cured ☐ Treatment completed ☐ Failure ☐ Defaulted ☐ Died
Date: ______________ Date: ______________ Date: ______________ Date: ______________
Signature: __________________________
Date: __________________________
Designation: __________________________

Send this part back to the referring unit as soon as the treatment outcome report is available

For use by institution where patient has been referred

Name of patient: __________________________ TB Registration No: __________________________
Age: ____________ Sex: ______ M ☑ F ☑
Date Referred/Transferred: __________________________
Date of Received at this institution on: __________________________
Signature: __________________________
Designation: __________________________
Name of institution from where patient was referred: __________________________
District: __________________________ Date: __________________________

Send this part to the Referring Unit as soon as patient has reported and registered and also sent the
treatment outcome to the center from where the patient was referred after completion of treatment.
## NATIONAL TUBERCULOSIS CONTROL PROGRAMME (NTP)
### Directorate General of Health Services, Bangladesh
### Requisition Form for Drugs

**Year:** Bi-annum: Jan-Jun / July-Dec: __________________________

**Name of Health Facility:** ______________________________________

**City/District/Upazila:** _________________________________________

**Name & Designation the person filling in the form:** __________________

**Name & Contact no. of the UH&FPO / Center chief:** ________________

<table>
<thead>
<tr>
<th>Adults</th>
<th>Children (≤ 15 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category I = (n)</td>
<td>Category II = (n)</td>
</tr>
</tbody>
</table>

### Number of registered cases during the previous quarter

### Drug requirements estimation

<table>
<thead>
<tr>
<th>Drug</th>
<th>1^st Quantity required for one quarter</th>
<th>2^nd Total for bi-annum (+Buffer)</th>
<th>3^rd Existing balance</th>
<th>4^th Amount to be supplied</th>
<th>5^th Actual amount supplied</th>
<th>6^th Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>4FDC</td>
<td>n x 180 ( \left[ \begin{array} {l} n \times 180 \end{array} \right] ) ( \text{Cat I} )</td>
<td>n x 270 ( \left[ \begin{array} {l} n \times 270 \end{array} \right] ) ( \text{Cat II} )</td>
<td>(b) = 3x(a)</td>
<td>(b) - (c)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2FDC</td>
<td>n x 360 ( \left[ \begin{array} {l} n \times 450 \end{array} \right] ) ( \text{Cat I} )</td>
<td>n x 450 ( \left[ \begin{array} {l} n \times 450 \end{array} \right] ) ( \text{Cat II} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[R60/H30] (Dispensable)</td>
<td>( \left[ \begin{array} {l} c_1 \times 360 \end{array} \right] ) ( \text{Cat I} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[R60/H30]Z150mg (Dispensable)</td>
<td>( \left[ \begin{array} {l} c_1 \times 180 \end{array} \right] ) ( \text{Cat I} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H 100 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R 150 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H 300 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R 450 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Z 500 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E 400 mg</td>
<td>( \left[ \begin{array} {l} n_1 \times 450 \end{array} \right] ) ( \text{Cat I} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S 1 g</td>
<td>( \left[ \begin{array} {l} n_1 \times 60 \end{array} \right] ) ( \text{Cat II} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inj. Water, 5ml</td>
<td>( \left[ \begin{array} {l} n_1 \times 60 \end{array} \right] ) ( \text{Cat I} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D/Syringe, 5cc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Multiply the number of patients (n/n/c) in each treatment category with the number needed for treatment of one patient.
2. Next bi-annum quantity = buffer stock (50% of bi-annum) is thrice the consumption of last quarter (300%).
3. Indicate the remaining balance from the drug ledger at the end of the previous quarter.
4. Use this column to mention drug(s) with expiry less than 6 months (give name, quantity & exact date of expiry).

**Prepared by:** __________________________
**UH&FPO/Center chief:** __________________________

**Checked by:** __________________________
**Controlling authority (e.g. C S):** __________________________

(Signature with date)

(Counter sign with Date)
### NATIONAL TUBERCULOSIS CONTROL PROGRAM - BANGLADESH

Directorate General of Health Services, Bangladesh.

Quarterly report on case finding of tuberculosis

<table>
<thead>
<tr>
<th>Name of District:</th>
<th>Name of Upazila/Address &amp; Ward No:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Name & Signature of UH&FPO/In-charge of DOTS/ Health Unit:

<table>
<thead>
<tr>
<th>Block 1: All TB cases registered (Excluding &quot;transfer in&quot; and chronic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary sputum smear microscopy positive</td>
</tr>
<tr>
<td>New cases (1)</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>------</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Block 2: Smear Positive New Cases (From Column 1 above)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMEAR POSITIVE NEW CASES, from column (1) above</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age-groups</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>5-9</td>
</tr>
<tr>
<td>Male</td>
<td>Female</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Block 3: Smear Negative Cases (From column-5 above)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age-groups</td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>0-4</td>
</tr>
<tr>
<td>Male</td>
</tr>
</tbody>
</table>

Patients Registered During: quarter [2023-09]

Date of Completion of this Form: Name, Signature & Contact no. of Person Completed the Form:

Population of the area:

Smear Positive Case Notification Rate:
### Block 4: New EP Cases (From column 6 above)

<table>
<thead>
<tr>
<th>Age-groups</th>
<th>04</th>
<th>5-14</th>
<th>15-24</th>
<th>25-34</th>
<th>35-44</th>
<th>45-54</th>
<th>55-64</th>
<th>&gt;64</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Female</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
</tbody>
</table>

### Block 5: No of Patients Referred by:

<table>
<thead>
<tr>
<th>Service</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
</tr>
</thead>
<tbody>
<tr>
<td>PP</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Non-PP</td>
<td>F</td>
<td>F</td>
<td>F</td>
</tr>
<tr>
<td>GFS</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>SS</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>VD</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>CV</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Govt. Hospital</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Private Hospital</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>TB Patient</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Other (Specify)</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
</tbody>
</table>

### Block 6: Laboratory Activity - Sputum smear microscopy

<table>
<thead>
<tr>
<th>No. of TB suspects examined</th>
<th>No. of TB suspects with positive sputum smear microscopy result</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>F</td>
<td>M</td>
</tr>
</tbody>
</table>

*This information to be included in the Lab report form.

### Block 7: TB/HIV activities

<table>
<thead>
<tr>
<th>No. of patients tested for HIV before or during TB treatment</th>
<th>No. of patients HIV positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>Female</td>
</tr>
</tbody>
</table>

*New Sputum smear
Re-treatment cases (specify)
Smear negative
Extra Pulmonary

<table>
<thead>
<tr>
<th>Suspect referral</th>
<th>No. of suspect referred for sputum test</th>
<th>No. of positive among tested individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>Female</td>
<td>Total</td>
</tr>
</tbody>
</table>

*Other previously treated cases include pulmonary cases with unknown history of previous treatment, previously treated sputum smear microscopy negative pulmonary cases and previously treated extrapulmonary cases. Transferred in and chronic cases are excluded.

---

### NATIONAL TUBERCULOSIS CONTROL PROGRAM BANGLADESH

Quarterly Report on Treatment Results of Pulmonary TB Patients Registered 12-15 months earlier

**Name of District:**

**Name of Upazila/Address & Ward No.:**

**Name & Signature of UH&EFO/In-charge of DOTS/Health Unit:**

**Patients Registered During:**

<table>
<thead>
<tr>
<th>Date of Completion of this Form:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarter</td>
</tr>
</tbody>
</table>

**Name, signature & contact no. of person completed the form:**

<table>
<thead>
<tr>
<th>Total No of Patients reported during the above quarter</th>
<th>Patient type</th>
<th>(1) Cured</th>
<th>(2) Treatment Completed</th>
<th>(3) Died</th>
<th>(4) Failure</th>
<th>(5) Defaulter</th>
<th>(6) Transferred out</th>
<th>Not Evaluated (7)</th>
<th>Grand Total (1 to 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>F</td>
<td>Total</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
</tr>
</tbody>
</table>

1. New Cases

- 1.1 Smear Positive
- 1.2 Smear Negative
- 1.3 EP

2. Re-treatment Cases

- 2.1 Reactions
- 2.2 Failures
- 2.3 Treatment after default
- 2.4 Other
- 2.5 Total

(2.1+2.2+2.3+2.4)

<table>
<thead>
<tr>
<th>No. of patients on CPT</th>
<th>No. of patient on ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>F</td>
</tr>
</tbody>
</table>

**Treatment Success Rate:**

1.1 sm +ve:............ 1.2 sm -ve:............ 2.5 result:............

*Includes TB Patients continuing on CPT started before TB diagnosis and those started during TB Treatment.

*Includes TB Patients continuing on ART started before TB diagnosis and those started during TB Treatment.
### NATIONAL TUBERCULOSIS CONTROL PROGRAM - BANGLADESH

**Quarterly Report on Sputum Conversion at 2/3 Months of Smear Positive Pulmonary Tuberculosis patients registered 3-6 month earlier**

<table>
<thead>
<tr>
<th>Total No of Primary Patient reported during the above quarter</th>
<th>Type of Patient</th>
<th>(1) Smear Negative</th>
<th>(2) Smear Positive</th>
<th>(3) Died</th>
<th>(4) Defaulted</th>
<th>(5) Transferred out</th>
<th>(6) Not Evaluated</th>
<th>Grand Total (1 to 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>F</td>
<td>T</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>1. New Cases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Smear Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Smear Negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Sputum conversion rate

- New: __________
- Retreatment: __________

---

### NATIONAL TUBERCULOSIS PROGRAMME, BANGLADESH

**Quarterly Report On Laboratory Findings Of Tuberculosis**

<table>
<thead>
<tr>
<th>Centre:</th>
<th>Upazilla:</th>
<th>District:</th>
<th>Division:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Name of Lab technologist(s): __________
- Date of report preparation: __________
- Technologist trained by the NTP: Yes/No
- No. of microscope in running condition: __________

#### Diagnostic Examinations (Case Finding)

<table>
<thead>
<tr>
<th>Quarter / Year</th>
<th>TB suspects tested (No. of people tested)</th>
<th>AFB positive cases (No. of positive tested)</th>
<th>Smears tested (No. of smears tested)</th>
<th>Positive Smears (1+2+&amp; 3+1+AFB/B100)</th>
<th>Only sample tested</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(a)</td>
<td>(b)</td>
<td>(c)</td>
<td>(d)</td>
<td>(e)</td>
</tr>
</tbody>
</table>

#### Follow-up Examinations

<table>
<thead>
<tr>
<th>Smears tested (No. of smears tested)</th>
<th>Positive Smears (1+2+ &amp; 3+)</th>
<th>Scanty (1+AFB/B100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(f)</td>
<td>(g)</td>
<td>(h)</td>
</tr>
</tbody>
</table>

- Total no. of smears tested (c+g) *1
- Total no. of (1+2+ & 3+)+smears (d+b) *2
- Total no. of Scanty Smears (g) *3
- Total no. of Negative Smears (w-y) *2
- Positive rate among TTB suspects (%) *4

---

- *1 This data will be used for planning of supplies;
- *2 This data will be used for quarterly report of re-checking in EQA centre;
- *3 This could be used to monitor programme performance;
- *4 This data will be used for quality control.

---

Copy to: Respected EQA centre
Prepared by: Lab Technologist
Approved by: UHFOP / Jr. Consultant / NGO Clinic Manager

---

79
জাতীয় যন্ত্র নিয়ন্ত্রণ কর্মসূচি

সেন্ট্রাল যন্ত্র রোগী প্রেরণের ফর্ম

যন্ত্রকর্মকর্তা রোগীর নামঃ-------------------------------------------
বয়সঃ ৪-----------------------------------------------
ঠিকানাঃ-----------------------------------------------

প্রেরনকারীর নামঃ--------------------------------- পদবীঃ
ঠিকানাঃ-----------------------------------------------

(৩ সতীরের অধিক কাশিয়া অশ্রুর প্রাধান লক্ষ্য)

(৩ সতীরের অধিক কাশিয়া অশ্রুর প্রাধান লক্ষ্য)
NATIONAL TUBERCULOSIS CONTROL PROGRAM-BANGLADESH  
Directorate General of Health Services  
Mohakhali, Dhaka  
Supervision Check List

Name of Centre: ___________________________  
District ___________________________

Catchmen Population:_________________________  
Estimated Number of TB patients:_________________________

Name of Supervisor:_________________________

Date of Visit:_________________________

Follow up of previous visit
Date of last visit: ......../ ......../ 200
Problems identified and recommendations of last visit:


Status of implementation according to recommendations:


Training status of health worker(s), including laboratory technologist, at the time of the visit:

<table>
<thead>
<tr>
<th></th>
<th>Satisfactory</th>
<th>Unsatisfactory</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Number of health worker(s) directly involved in TB Control programme
   i) Health Center
   ii) Peripheral Health Workers

2. Number of Health Worker(s) present on the day of visit

3. Interview with health workers/DOTS providers (If available during visit):
   * Knowledge of the disease
     Satisfactory [ ]  Unsatisfactory [ ]
   * Do they refer suspects
     Yes [ ]  No [ ]
   * Do they supervise treatment
     Yes [ ]  No [ ]
   * Do they follow-up drug reaction cases
     Yes [ ]  No [ ]
4. Interview some patients to check their knowledge and satisfaction of services available (Answered satisfactorily)

- Name of the disease he/she is suffering from? 
- How can we suspect whether a person has TB or not?
- Duration of treatment
- Understanding of irregular treatment
- Danger of irregular treatment
- Availability of free treatment (who and where)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of the disease he/she is suffering from</td>
<td></td>
<td></td>
</tr>
<tr>
<td>How can we suspect whether a person has TB or not?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Understanding of irregular treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Danger of irregular treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Availability of free treatment (who and where)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. Availability of NTP manual / Laboratory Manual (Available)

<table>
<thead>
<tr>
<th>Availability</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

6. Documentation:

6.1 Treatment Cards
- Complete [ ]
- Incomplete [ ]

6.2 Laboratory register (check last quarter)
- a. Number of suspect with negative smear [ ]
- e. Number of cases registered in TB register [ ]
- b. Number of suspect with positive smear [ ]
- f. No. of +ve smear among follow-up exam [ ]
- c. No. of follow up examination [ ]
- g. Case/Smear positivity rate [ ]
- d. No. suspects with < 3 smear examination [ ]
- h. % of suspects with < 3 smear examination [ ]

6.3 TB register:
- 6.3.1 Cross check whether all +ve from lab register are registered [ ]

6.4 Patient Statistics (Available)
- i) Case registered [ ]
- ii) Sputum conversion [ ]
- iii) Cure rate [ ]

7. Laboratory services:

7.1 Microscope functioning
- i) Presence of fungus [ ]
- ii) Preservation of Microscope [ ]

7.2 Examining slides
- 7.2.1 Size of the smear appropriate [ ]
- 7.2.2 Thickness of the smear appropriate [ ]
- 7.2.3 Staining of slides appropriate [ ]

7.3 Quality Assurance in place [ ]
7.4 Regular Collection of slides for EQA [ ]
7.5 Feed back of EQA available [ ]
7.6 Action taken [ ]
7.7 Disposal of lab. wastage (properly done) [ ]
8. **TB register**

8.1. Cross check whether all +ve from lab register are registered

8.2. Information of patients

8.3. **Case Detection:**

8.3.1 Case registered in last quarter:

8.3.2 No. of new smear +ve cases registered:

8.3.3 Case detection rate: (No. of cases in last 4 quarter× 100)

8.3.4 No. of expected cases for a year

8.3.5 Check for the correctness of the last quarter report

8.4 Sputum conversion

8.4.1 No. of new smear +ve cases that became negative at the end of the intensive phase/No. of new smear positive cases registered (previous quarter)

8.4.2 Check for the correctness of the last quarterly report

8.4.3 Sputum conversion rate:

8.5 Treatment outcome:

8.5.1 No. of new smear positive cured / No. of new smear positive cases registered (of 9-12 months ago)

8.5.2 Check for the correctness of the quarterly report

8.5.3 Treatment success rate:

9. **Management for Drugs and other logistics**

9.1. Drugs:

9.1.1 Was the indent form filled in and calculated properly?

9.1.2 Was there any stock-out in the last quarter or now?

9.1.3 Are Anti-TB drugs stored properly on pallets/shelves?

9.1.4 Are Bin Cards maintained with Expiry Dates?

9.1.5 Check whether FEFO and FIPO are applied during storage and distribution

9.1.6 Conformity amongst Stock Ledger, Bin Card and Random Physical Inventory:

9.1.7 Is there any drug with shelf life less than 6 months?
9.2. **Other logistics:**

9.2.1 Reagents (carbol fuchsine, methyl blue, HCL etc):

- Sufficient [ ]
- Insufficient [ ]
- Stock-out (Please specify) [ ]

9.2.2 Are drugs and chemicals/reagents stored separately?

- Yes [ ]
- No [ ]
- Please specify, if no [ ]

9.2.3 Forms / cards / registers:

- Sufficient [ ]
- Insufficient [ ]
- Stock-out (Please specify) [ ]

9.2.4 Other logistics (Please specify)

- Sufficient [ ]
- Insufficient [ ]
- Stock-out (Please specify) [ ]

10. **ACSM Activities:**

   i) Presence of Posters / Sticker
   - Yes [ ]
   - No [ ]

   ii) Display of poster / sticker
   - Yes [ ]
   - No [ ]

   iii) Presence, distribution and use of educational materials
        (Leaflet, flip, char, flash chart, brochure)
   - Yes [ ]
   - No [ ]

   iv) Signboard with DOTS facilities in front of health center
   - Yes [ ]
   - No [ ]

   v) Health education on TB by health facility
   - Yes [ ]
   - No [ ]

   vi) DOTS committee meeting held regularly
   - Yes [ ]
   - No [ ]

   vii) DOTS committee meeting minutes available
   - Yes [ ]
   - No [ ]

11. **Name and designation of key personnel's present during supervision:**

   1. .................................................................
   2. .................................................................
   3. .................................................................

12. **Recommendation / Comments of supervisor**

   ........................................................................
   ........................................................................
   ........................................................................
   ........................................................................
   ........................................................................
   ........................................................................
Quantities of Drug needed for the different categories of patients

Quantities needed for Cat I, adult patients (body weight 38-54 kg)
2(RHZE)/4(RH):

<table>
<thead>
<tr>
<th>INTENSIVE PHASE: (DAILY)</th>
<th>DOSE</th>
<th>NO. OF TABLETS PER ADULT PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 FDC tablet containing:</td>
<td>3 tablets daily for 60 doses</td>
<td>60 X 3 = 180</td>
</tr>
<tr>
<td>R 150 mg/H75 mg/Z400 mg/ E275 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CONTINUATION PHASE (DAILY)
<table>
<thead>
<tr>
<th>DOSE</th>
<th>NO. OF TABLETS PER ADULT PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 FDC tablet containing:</td>
<td>120 X 3 = 360</td>
</tr>
<tr>
<td>R 150 mg/H75 mg</td>
<td>120 doses</td>
</tr>
</tbody>
</table>

Quantities needed for Cat II, adult patients (body weight 38-54 kg):
2S(RHZE)/1(RHZE)/5(RH)E:

<table>
<thead>
<tr>
<th>INTENSIVE PHASE: (DAILY)</th>
<th>DOSE</th>
<th>NO. OF TABLETS / INJECTION PER ADULT PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 FDC tablet containing:</td>
<td>3 tablets daily for 90 doses</td>
<td>90 X 3 = 270</td>
</tr>
<tr>
<td>R 150 mg/H75 mg/Z400 mg/ E275 mg</td>
<td>1 vials daily for 60 doses</td>
<td>60</td>
</tr>
<tr>
<td>Streptomycin vials 1 gm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water for injection vials use with Streptomycin</td>
<td>1 vials daily for 60 doses</td>
<td>60</td>
</tr>
</tbody>
</table>

CONTINUATION PHASE (DAILY)
<table>
<thead>
<tr>
<th>DOSE</th>
<th>NO. OF TABLETS PER ADULT PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 FDC tablet containing:</td>
<td>150 X 3 = 450</td>
</tr>
<tr>
<td>R 150 mg/H75 mg</td>
<td>150 doses</td>
</tr>
<tr>
<td>Ethambutol 400 mg</td>
<td>150 doses for 5 months =</td>
</tr>
</tbody>
</table>

Quantities needed for all children:
2(RHZ)E/4(RH)

<table>
<thead>
<tr>
<th>INTENSIVE PHASE: (DAILY)</th>
<th>DOSE</th>
<th>NO. OF TABLETS PER CHILD PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3FDC tablet containing:</td>
<td>3 tablets daily for 60 doses</td>
<td>60 X 3 = 180</td>
</tr>
<tr>
<td>R 60 mg/H30 mg/Z1.50 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethambutol 100 mg</td>
<td>4 tablet daily for 60 doses</td>
<td>60 X 4 = 240</td>
</tr>
<tr>
<td>* Ethambutol 400 mg</td>
<td>1 tablets daily for 60 doses</td>
<td>60 X 1 = 60</td>
</tr>
</tbody>
</table>

CONTINUATION PHASE (DAILY)
<table>
<thead>
<tr>
<th>DOSE</th>
<th>NO. OF TABLETS PER CHILD PATIENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>2FDC tablet containing:</td>
<td>120 X 3 = 360</td>
</tr>
<tr>
<td>R 60 mg/H30 mg</td>
<td>120 doses</td>
</tr>
</tbody>
</table>

* for children weighing 20 kg or more
A. Smear-positive (sm+) detected last quarter: ...................

B. Number of labs to be supplied: ................................

<table>
<thead>
<tr>
<th></th>
<th>Factor (C)</th>
<th>Calculation</th>
<th>Amount calculated (D)</th>
<th>Amount in stock (E)</th>
<th>Amount indented (F=2*D-E)</th>
<th>Amount received</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic fuchsin</td>
<td>1 gram / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenol crystals</td>
<td>5 gram / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methanol</td>
<td>10 ml / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(or denatured ethanol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylene blue</td>
<td>0.1 gram / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulphonic Acid cone</td>
<td>33 ml / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burning spirit</td>
<td>50 ml / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>slides</td>
<td>36 pc / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sputum Containers</td>
<td>36 pc / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bamboo sticks</td>
<td>36 pc / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immersion oil</td>
<td>2 ml / sm+</td>
<td>A*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xylene</td>
<td>25 ml / sm+</td>
<td>B*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toilet paper rolls</td>
<td>3 rolls / clinic</td>
<td>B*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filter paper pcs</td>
<td>20 pcs / clinic</td>
<td>B*C=</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>